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Abstract		
The	 requirement	 for	 next	 generation	 anti-malarials	 to	 be	 both	 curative	 and	 transmission	
blocking	 necessitate	 the	 identification	 of	 new	 druggable	 molecular	 pathways.	 Here	 we	
identify	a	selective	inhibitor	to	the	Plasmodium	falciparum	protein	kinase	PfCLK3	which	we	
use	 in	 combination	 with	 chemogenetics	 to	 validate	 PfCLK3	 as	 a	 drug	 target	 acting	 at	
multiple	 parasite	 life	 stages.	 Consistent	 with	 a	 role	 for	 PfCLK3	 in	 RNA	 splicing,	 inhibition	
results	in	the	down-regulation	of	>400	essential	parasite	genes.	Inhibiting	plasmodium	CLK3	
mediates	 rapid	 killing	 of	 asexual	 blood	 stage	 P.	 falciparum	 and	 blockade	 of	 gametocyte	
development	 preventing	 transmission,	 as	 well	 as	 showing	 parasiticidal	 activity	 against	 P.	
berghei	and	P.	knowlesi.	Hence,	our	data	establishes	PfCLK3	as	a	target	with	the	potential	to	
deliver	both	symptomatic	treatment	and	transmission	blocking	in	malaria.						
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Introduction	
Despite	artemisinin-based	combinations	therapies	offering	effective	frontline	treatment	for	
malaria	there	are	still	over	200	million	cases	of	malaria	worldwide	per	annum	resulting	in	an	
estimated	0.5	million	deaths.	This,	combined	with	the	fact	that	there	is	now	clear	evidence	
for	 the	 emergence	 of	 resistance	 to	 not	 only	 artemisinin	 (1,	 2)	 but	 also	 to	 partner	 drugs	
including	piperaquine	and	mefloquine	 (3,	4)	means	that	 there	 is	an	urgent	need	 for	novel	
therapeutic	 strategies	 to	 not	 only	 cure	 malaria	 but	 also	 to	 prevent	 transmission.	 Global	
phospho-proteomic	 studies	 on	 the	most	 virulent	 species	 of	 human	malaria,	P.	 falciparum	
have	 established	 protein	 phosphorylation	 as	 a	 key	 regulator	 of	 a	wide	 range	 of	 essential	
parasite	processes	(5-8).	Furthermore,	of	the	65	eukaryotic	protein	kinases	 in	the	parasite	
kinome	 (9),	 over	 half	 have	 been	 reported	 to	 be	 essential	 for	 blood	 stage	 survival	 (8-12).	
These	studies,	together	with	the	generally	accepted	potential	of	targeting	protein	kinases	in	
the	 treatment	 of	 numerous	 human	 diseases	 (13,	 14),	 suggests	 that	 inhibition	 of	 parasite	
protein	kinases	might	offer	a	viable	strategy	for	the	treatment	of	malaria	(6,	15)	
To	 directly	 test	 this	 hypothesis	 we	 focused	 here	 on	 one	 of	 the	 four	 members	 of	 the	 P.	
falciparum	cyclin-dependent	like	((CLK)	protein	kinase	family,	PfCLK3	(PF3D7_1114700),	an	
essential	protein	kinase	in	maintaining	the	asexual	blood	stage	of	both	P.	falciparum	(8,	12)		
and	P.	berghei	(10).	In	mammalian	cells	the	CLK	protein	kinase	family	and	the	closely-related	
SRPK	 family	 are	 crucial	mediators	 of	multiple	 phosphorylation	 events	 on	 splicing	 factors,	
including	 serine-arginine-rich	 (SR)	 proteins,	 which	 are	 necessary	 for	 the	 correct	 assembly	
and	catalytic	activity	of	spliceosomes	(reviewed	in	(16)).	A	key	member	of	the	human	CLK-
family	 is	 the	 splicing	 factor	 kinase	 PRP4	 kinase	 (PRPF4B),	 which	 homology-based	 studies	
have	 identified	 as	 the	 closest	 related	 human	 kinase	 to	 PfCLK3(17,	 18).	 PRPF4B	 plays	 an	
essential	 role	 in	 the	 regulation	 of	 splicing	 by	 phosphorylation	 of	 accessory	 proteins	
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associated	with	the	spliceosome	complex	(19).	 	The	finding	that	PfCLK3	can	phosphorylate	
SR	 proteins	 in	 vitro	 (20)	 supports	 the	 notion	 that	PfCLK3,	 like	 the	 other	members	 of	 the	
PfCLK	family	(17),	plays	an	essential	role	in	parasite	pre-mRNA	processing	(18).		
	
High	throughput	screen	identifies	selective	PfCLK3	inhibitors	
We	established	high-throughput	 inhibition	assays	 for	 two	essential	members	of	 the	PfCLK	
family	namely	PfCLK1	and	PfCLK3	 (fig.	S1).	Both	of	 these	protein	kinases	were	purified	as	
active	 recombinant	 proteins	 (fig.	 S2A)	 and	 used	 in	 a	 high	 throughput	 time-resolved	
florescence	 resonance	 energy	 transfer	 (TR-FRET)	 showing	 robust	 reproducibility	 in	 1536	
assay	 format	 (	 Z’>0.7)	 (fig.	 S2B-H).	 This	 assay	 was	 used	 to	 screen	 24,619	 compounds,	
comprised	of	13,533	compounds	in	the	Tres	Cantos	Anti-Malarial	Set	(TCAMS)	(21),	1115	in	
the	Protein	Kinase	 Inhibitor	 Set	 (PKIS)	 (22)	 and	9,970	MRCT	 index	 library	 (23),	 at	 a	 single	
dose	 (10µM).	 Hits	 were	 defined	 as	 those	 compounds	 that	 were	 positioned	 >3	 standard	
deviations	from	the	mean	of	the	%	inhibition	distribution	curve	(Fig.	1A,B)	and	which	also	
showed	>40%	inhibition.	This	identified	2579	compounds	(consisting	of	MRCT=250,	PKIS=4,	
TCAMS=2325)	which	 together	with	 the	259	 compounds	 identified	as	 “the	 kinase	 inhibitor	
set”	 from	within	 the	Medicines	 for	Malaria	 Venture	 (MMV)	 box,	 a	 collection	 of	 400	 anti-
malarial	 compounds	 (24),	were	used	 to	 generate	 concentration	 inhibition	 curves	 (Fig.	 1C)	
(table	S1).	 	Based	on	the	selectivity	criteria	of	more	 than	a	>1.5	 log	 fold	difference	 in	 the	
negative	 logarithm	of	 the	 half	maximal	 inhibition	 (pIC50),	 28%	of	 the	 hits	 showed	 specific	
inhibition	 of	 PfCLK1	 and	 13%	 specifically	 inhibited	 PfCLK3	 whilst	 23%	 of	 the	 compounds	
inhibited	both	PfCLK3	and	PfCLK1	with	the	remainder	(36%)	being	inactive	(Fig.	1C,D)	(table	
S1).	Exemplar	molecules	from	each	of	these	three	classes	are	shown	in	fig.	S3.		
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Highlighted	in	Figure	1c	is	TCMDC-135051	which	showed	the	highest	selectivity	and	efficacy	
for	 inhibition	 of	 PfCLK3.	 Furthermore,	 TCMDC-135051	 showed	 ~100	 fold	 lower	 activity	
against	the	closely	related	human	kinase	CLK2	(29%	sequence	 identity	with	PfCLK3)	 (table	
S1).	 	 Similarly,	 TCMDC-135051	 showed	 no	 evidence	 of	 interacting	 with	 the	 human	
orthologue	 of	 PfCLK3,	 PRPF4B.	 This	 was	 seen	 in	 thermostability	 assays,	 using	 differential	
scanning	fluorimetry	(DSF),	where	staurosporine,	acting	as	a	positive	control,	increased	the	
melting	 temperature	 of	 PRPF4B	 by	 2.40±0.14oC.	 In	 contrast,	 TCMDC-135051	 showed	 no	
significant	 change	 in	 PRPF4B	 thermostability	 (fig.	 S4A).	 Furthermore,	 in	 a	 mass	
spectrometry	 based	 PRPF4B	 activity	 assay	 the	 published	 inhibitor,	 Compound	 A	 (25),	
showed	 significant	 inhibition	 of	 PRPF4B	whereas	 TCMDC-135051	 at	 concentrations	 up	 to	
50µM	showed	no	 inhibitory	activity	 (fig.	 S4B).	 In	 further	 counter	 screens,	 TCMDC-135051	
showed	no	significant	activity	against	the	P.	falciparum	protein	kinases,	PfPKG	and	PfCDPK1	
(fig.	 S5A-C).	 Thus,	 TCMDC-135051	 showed	 selective	 inhibition	 of	PfCLK3	when	 compared	
against	the	closely	related	human	kinases	PRPF4B	and	CLK2,	as	well	as	the	closest	parasite	
kinase,	PfCLK1,	and	other	parasite	kinases	(PfPKG,	PfCDPK1).	
TCMDC-135051	 is	 a	 member	 of	 a	 series	 of	 molecules	 that	 were	 contained	 in	 the	 high	
throughput	 screen	 (HTS)	 with	 the	 same	 chemical	 scaffold.	 This	 series	 showed	 similar	
inhibitory	 activity	 against	 PfCLK3	 (fig.	 S6).	 Note	 that	 the	 TCMDC-135051	 is	 part	 of	 the	
TCAMs	and	has	previously	been	shown	to	have	anti-parasiticidal	activity	(EC50=320nM)	and	
the	 structure	has	previously	 been	published	 (21).	 Resynthesis	 of	 TCMDC-135051	 together	
with	 nuclear	 magnetic	 resonance	 (NMR)	 analysis	 has	 however	 determined	 the	 correct	
structure	for	TCMDC-135051	to	be	the	one	shown	in	Fig.	1C	and	fig.	S3.		
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Parasite	strains	resistant	to	TCMDC-135051	show	mutations	in	PfCLK3	
We	 next	 sought	 to	 confirm	 that	 PfCLK3	 was	 the	 target	 of	 TCMDC-135051	 parasiticidal	
activity.	 Exposing	 P.	 falciparum	 Dd2	 parasites	 to	 increasing	 concentrations	 of	 TCMDC-
135051,	 resulted	 in	 emergence	 of	 three	 independent	 lines	 that	 showed	 decreased	
sensitivity	to	TCMDC-135051	but	no	change	in	sensitivity	to	chloroquine	or	artemisinin	(Fig.	
2A,	Table	1).	Whole	genome	sequencing	of	the	three	resistant	 lines	revealed	mutations	 in	
PfCLK3	(lines	TM051A	and	TM051C)	and	a	mutation	in	the	putative	RNA	processing	protein,	
PfUSP-39	 (PF3D7_1317000)(line	 TM051B,	 Table	 1,	 Fig.	 2B).	 The	 resistant	 clone	 TM051A,	
which	 contained	 the	mutation	 P196R	 in	 the	 N-terminal	 region	 outside	 the	PfCLK3	 kinase	
domain	(Fig.	2B),	showed	the	smallest	change	in	sensitivity	to	TCMDC-135051	(4.2	fold	shift	
in	 the	 EC50	 compared	 to	 parental	 Dd2	 parasites).	 Examination	 of	 the	 in	 vitro	 enzymatic	
properties	of	the	P196R	mutant	found	in	TM051A	did	not	detect	any	significant	changes	in	
enzyme	 kinetics	 or	 sensitivity	 to	 inhibition	 by	 TCMDC-135051	 compared	 to	 the	wild	 type	
kinase	suggesting	that	this	mutation	could	potentially	stabilise	the	protein	or	be	otherwise	
involved	in	the	interaction	between	PfCLK3	and	its	substrates	or	regulatory	proteins.		
The	 line,	 TM051C,	 containing	an	H259P	mutation	 in	PfCLK3	 showed	 the	 largest	degree	of	
resistance	to	TCMDC-135051	with	a	shift	in	the	EC50	of	>11	fold	in	the	death	curve	(Fig.	2C,	
Table	 1).	 Evaluation	 of	 the	 enzymatic	 properties	 of	 the	 H259P	mutant	 revealed	 that	 the	
mutant	kinase	possessed	~3	times	the	activity	of	the	wild	type	kinase	whereas	the	Km	for	
ATP	 was	 similar	 between	 mutant	 and	 wild	 type	 kinases	 (Fig.	 2D,E).	 The	 fact	 that	 H259	
resides	 outside	 of	 the	 kinase	 domain	 suggests	 that	 this	 amino	 acid	 is	within	 a	 regulatory	
region	that	controls	enzymatic	activity.		
In	contrast	to	the	other	two	resistant	lines,	TM051B	did	not	contain	a	mutation	in	PfCLK3		
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but	 rather	 contained	 a	mutation	 (F103I)	 within	 the	 putative	 zinc-finger	 ubiquitin	 binding	
domain	 of	 ubiquitin	 specific	 peptidase-39	 (PfUSP39).	 Importantly,	 the	 human	 and	 yeast	
orthologues	 of	PfUSP39	 (snRNP	 assembly-defective	 protein-1	 (Sad1))	 are	members	 of	 the	
deubiquitinase	 family	 that	 are	 essential	 components	 of	 the	 U4/U6-U5	 tri-snRNP	 complex	
necessary	 for	 spliceosome	 activity	 (26-28).	 The	 position	 of	 the	 F103I	mutation	within	 the	
zinc-finger	ubiquitin	binding	domain	of	USP39	may	be	of	significance	since	this	domain	has	
been	 implicated	 in	 the	 interaction	 of	 USP39/Sad1	with	 the	 spliceosome	 (27).	 Hence,	 the	
involvement	 of	 USP39	 in	 the	 same	 pathway/function	 as	 PfCLK3,	 together	 with	 the	
mutations	 found	 in	PfCLK3	 itself	 in	 the	other	 two	resistant	 lines,	 supports	 the	notion	 that	
the	parasiticidal	activity	of	TCMDC-135051	is	via	inhibition	of	PfCLK3.			
	
Genetic	target	validation	of	PfCLK3	
To	further	confirm	PfCLK3	as	the	target	of	TCMDC-135051	parasiticidal	activity	a	variant	of	
PfCLK3	was	designed	that	showed	reduced	sensitivity	 to	TCMDC-135051.	To	generate	 this	
variant,	advantage	was	taken	of	the	highly	selective	inhibition	of	PfCLK3	over	PfCLK1	shown	
by	 TCMDC-135051.	 By	 exchanging	 amino	 acids	 within	 the	 sub-domain	 V	 of	 the	 PfCLK3	
kinase	domain	with	equivalent	residues	in	the	kinase	domain	of	PfCLK1	(fig.	S1)	a	variant	of	
PfCLK3	was	generated	where	glycine	449	 in	PfCLK3	was	substituted	with	a	proline	residue	
(G449P)	(Fig.	3A).	This	recombinant	variant	protein	showed	a	~3	fold	log	shift	in	sensitivity	
for	 inhibition	by	TCMDC-135051	 (Fig.	3B,C)	 (PfCLK3	pIC50=7.35±0.12	 (IC50=0.04µM),	G449P	
pIC50=4.66±0.16	(IC50=21.87µM)).	The	G449P	variant	also	showed	a	slightly	lower	enzymatic	
activity	 (Fig.	3D)	 (PfCLK3	Vmax=1.24,	G449P	Vmax=0.88)	but	higher	Km	 for	ATP	 (fig.	 S7A)	
(PfCLK3	 Km=6.29,	 G449P	 Km=81.3)	 compared	 to	 wild	 type	 PfCLK3.	 Single	 cross	 over	
homologous	 recombination	 targeting	 the	PfCLK3	 locus	with	a	construct	designed	 to	 insert	
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the	coding	sequence	for	G449P	mutant	(Fig.	3E)	generated	two	independent	clones	(A3	and	
A8),	 which	 expressed	 the	 G449P	 mutant	 in	 place	 of	 the	 wild	 type	 PfCLK3	 (Fig.	 3F,G).	
Integration	of	the	plasmid	at	the	target	locus	was	verified	by	PCR	of	genomic	DNA	(Fig.	3F),	
and	Western	blotting	confirmed	expression	of	the	G449P	mutant	which	was	epitope	tagged	
with	a	haemaggultinin	(HA)	tag	at	the	C-terminus	(Fig.	3G).	The	growth	rate	of	the	G449P	
expressing	mutant	 parasites	were	 not	 significantly	 different	 from	 control	 3D7	 parasites	
(fig.	S7B).	Importantly,	the	activity	of	TCMDC-135051	in	parasite	viability	assays	was	seen	to	
be	 significantly	 reduced	by	 ~1.5	 log	units	 in	 both	 clones	of	G449P	 (Fig.	 3H)	 (the	negative	
logarithm	of	the	half	maximal	effect	(pEC50)	of	TCMDC-135051	in	the	Dd2	wild	type	=	6.35	±	
0.038	(EC50=	0.45µM)	and	in	the	A3	strain	=	4.86	±	0.13	(EC50=	13.80µM)	and	the	A8	strain	=	
4.94	 ±	 0.051	 (EC50=	 11.48µM)),	 providing	 further	 evidence	 that	 TCMDC-135051	 kills	
parasites	via	inhibition	of	PfCLK3.	
Previous	efforts	to	make	inhibitor-insensitive	versions	of	apicomplexan	protein	kinases	have	
focused	on	the	mutation	of	the	gate	keeper	residue,	a	key	residue	in	the	ATP	binding	pocket	
that	can	provide	steric	hindrance	to	ATP	competitive	protein	kinase	inhibitors			(5,	29,	30).	In	
contrast,	our	approach	was	based	on	a	comparison	of	residues	between	two	highly	related	
kinases	(PfCLK1	and	PfCLK3)	that	showed	differential	sensitivity	to	an	inhibitor.	By	swapping	
residues	 between	 the	 kinases	we	 introduced	 inhibitor	 in-sensitivity	 into	 our	 target	 kinase	
(e.g.	PfCLK3)	in	a	strategy	that	could	be	applied	to	other	protein	kinases.	
	
Inhibition	of	PfCLK3	prevents	trophozoite	to	schizont	transition		
To	 characterize	 the	 phenotypic	 response	 to	 PfCLK3	 inhibition	 and	 to	 understand	 PfCLK3	
function,	 P.	 falciparum	 3D7	 parasites	 synchronised	 at	 ring	 stage	 (time	 point	 zero)	 were	
treated	with	TCMDC-135051	(1µM).		The	parasites	progressed	to	late	ring	stage	(time	point	
	 10	
20	hours)	(Fig.	4A)	but	did	not	progress	further	to	trophozoite	stage	(time	point	30	and	40	
hours),	arresting	with	a	condensed	and	shrunken	appearance	(Fig.	4A).	Similar	effects	were	
observed	if	the	parasites	were	treated	at	mid	ring	stage	(time	point	10	hours).	Treatment	of	
parasite	 at	 later	 time	points	 (20	 hours	 or	 30	 hours)	 blocked	development	 of	 the	parasite	
from	trophozoite	to	schizont	stage.	 	The	fact	that	the	parasites	at	the	schizont	stage	were	
not	viable	was	 further	evidenced	by	 the	absence	of	 ring	 stage	parasites	when	 the	culture	
was	 continued	 to	 the	 50-hour	 time	 point	 (Fig.	 4A).	 These	 data	 indicated	 that	 PfCLK3	
inhibition	prevented	the	transition	of	the	parasites	at	early	(ring	to	trophozoite)	as	well	as	
late	stages	(trophozoite	to	schizont)	of	development	and	importantly	did	not	allow	parasites	
to	 reach	 to	 the	 next	 invasion	 cycle	 (Fig.	 4A).	 These	 data	 further	 indicated	 that	 PfCLK3	
inhibition	resulted	in	rapid	killing	with	no	evidence	that	the	compound	results	in	quiescence	
from	 which	 the	 parasite	 can	 recover	 following	 drug	 withdrawal.	 These	 features	 were	
confirmed	in	parasite	reduction	rate	(PRR)	assays,	which	showed	that	treatment	of	parasites	
with	 ten	 fold	EC50	of	TCMDC-135051	completely	killed	 the	parasite	 in	48	hours	and	viable	
parasites	 could	 not	 be	 observed	 despite	 maintaining	 the	 parasite	 culture	 for	 28	 days	
following	withdrawal	of	TCMDC-135051	(Fig.	4B).			
	
Inhibition	of	PfCLK3	disrupts	transcription	
Since	PfCLK3	has	been	proposed	 to	 regulate	RNA	processing	 (20)	and	 is	 closely	 related	 to	
the	human	kinases	PRPF4B	and	CLK2	that	are	involved	in	RNA	splicing	(19)	we	investigated	
changes	in	gene	transcription	in	parent	Dd2	parasites	and	the	drug-resistant	stain	TM051C,	
in	response	to	exposure	to	TCMDC-135051.	RNA	isolated	from	trophozoite	stage	parasites	
was	extracted	following	a	short	60	minute	treatment	with	TCMDC-135051	(1µM),	a	period	
of	time	in	which	the	Dd2	and	TM051C	parasites	maintained	normal	morphology.		Genome-
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wide	transcriptional	patterns	were	determined	using	oligonucleotide	microarray	chips	that	
probed	5752	P.	 falciparum	 genes	 (31).	Under	 these	 conditions	 779	 gene	 transcripts	were	
significantly	down-regulated	in	response	to	PfCLK3	inhibition	 in	the	Dd2	parasites	and	155	
genes	 were	 up-regulated	 (Fig	 4C,	 table	 S2).	 That	 the	 majority	 of	 these	 transcriptional	
changes	were	due	 to	 inhibition	of	PfCLK3	and	not	off-target	events	was	supported	by	 the	
fact	that	under	the	same	conditions	only	6	genes	were	up-regulated	and	88	down-regulated	
in	the	resistant	TM051C	parasite	strain	(Fig.	4D,	table	S3).	By	subtracting	the	transcriptional	
changes	observed	in	the	TM051C	strain,	defined	here	as	“off-target”,	from	those	observed	
with	 the	 Dd2	 parent,	 the	 transcriptional	 changes	 due	 to	 “on-target”	 inhibition	 of	 PfCLK3	
were	 defined	 (table	 S4).	 Among	 these	 “on-target”	 down-regulated	 genes	 were	 those	
involved	 in	 key	 parasite	 processes	 such	 as	 egress	 and	 invasion,	 cytoadherence,	 parasite	
protein	 export	 and	 involvement	 in	 sexual	 stages	 as	 well	 as	 house-keeping	 functions	
including	metabolism,	 RNA	processing,	 lipid	modification	 and	mitochondrial	 function	 (Fig.	
4E,	 table	 S4).	 Importantly,	 of	 the	 696	 “on-target”	 genes	 identified	 as	 down-regulated	 by	
PfCLK3	inhibition	(table	S4),	425	matched	those	that	have	recently	been	determined	to	be	
essential	for	asexual	P.	falciparum	survival	(12)	(table	S4).		
Gene	ontology	enrichment	analysis	was	used	to	determine	biological	functions	that	were	
disproportionally	down-regulated	by	PfCLK3	inhibition.	In	this	analysis,	genes	associated	with	key	
biological	functions	particularly	protein	modification,	phospholipid	biosynthesis	and	lipid	
modification	were	significantly	over-represented	amongst	those	genes	that	were	down-regulated	
(fig.	S8,	table	S5). Importantly,	93%	of	the	“on-target”	down-regulated	genes	contained	
introns	(Fig.	4F,	table	S4),	compared	to	52%	of	genes	in	the	P.	falciparum	genome	that	are	
annotated	as	containing	introns(32)	(Fig.	4G).	Hence,	PfCLK3	inhibition	significantly	affected	
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transcription	of	genes	that	contained	introns	(p	<	0.0001,	Pearson	chi-squared	test),	further	
supporting	its	role	in	splicing	
It	was	of	interest	that	in	addition	to	the	nearly	700	genes	down-regulated	in	response	to	
PfCLK3	inhibition	there	were	154	genes	that	were	significantly	up-regulated	(table	S4).		
Amongst	these	were	genes	associated	with	RNA	processing,	such	as	splicing	factor	1	
(PF3D7_1321700)	and	pre-mRNA-splicing	factor	SYF1	(PF3D7_1235900),	indicating	that	at	
least	some	of	the	up-regulated	genes	may	represent	compensatory	mechanisms.	In	
support	of	this	notion	was	the	finding	that	PfCLK3	itself	was	within	the	up-regulated	genes		
(table	S4).	 
	
Cross	species	and	in	vivo	activity	of	TCMDC-135051	
It	 might	 be	 predicted	 that	 the	 close	 similarity	 between	 orthologues	 of	 CLK3	 in	 different	
malaria	parasites	 species	would	 result	 in	TCMDC-135051	showing	similar	activities	against	
CLK3	from	different	Plasmodium	species.	This	indeed	was	the	case	as	in	vitro	kinase	assays	
using	 recombinant	 PvCLK3	 (P.	 vivax)	 and	 PbCLK3	 (P.	 berghei)	 (fig.	 S9A,B),	 showed	 that	
TCMDC-135051	had	near	equipotent	 inhibition	at	these	two	orthologues	with	pIC50	values	
of	 7.47	 ±	 0.12	 (IC50=0.033µM)	 and	 7.86	 ±	 0.10	 (IC50=0.013µM)	 respectively	 (fig.	 S9A,B).	
Furthermore,	in	asexual	blood	stage	cultures	of	both	P.	knowlesi	(an	experimental	model	for	
P.	vivax)	and	P.	berghei	(a	rodent	malaria	model	used	for	in	vivo	drug	testing	(33)),	inhibition	
of	PfCLK3	by	TCMDC-135051	resulted	 in	parasiticidal	activity	at	both	of	these	Plasmodium	
species	(Fig.	5A,B).	The	potent	and	efficacious	effects	of	TCMDC-135051	in	blood	P.	berghei	
cultures	prompted	an	investigation	of	the	in	vivo	activity	of	TCMDC-135051	in	mice	infected	
with	P.	berghei.	Twice	daily	intraperitoneal	dosing	of	TCMDC-135051	into	mice	infected	with	
P.	berghei	resulted	in	a	dose-related	reduction	in	parasitaemia	over	a	6	day	infection	period	
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where	the	maximal	dose	(50mg/kg)	resulted	 in	near	complete	clearance	of	parasites	 from	
peripheral	blood	(Fig.	5C).		
	
Activity	of	TCMDC-135051	at	liver	invasion	and	sporozoite	development	
TCMDC-135051	showed	potent	activity	against	P.	berghei	sporozoites	in	a	liver	invasion	and	
development	 assay	 (34)	 in	 which	 the	 compound	 showed	 a	 pEC50	 value	 of	 6.17	 ±	 0.10	
(EC50=0.40µM)	 (fig.	 S11),	 although	 hepatocyte	 toxicity	 (fig.	 S11)	 was	 observed	 but	 only	
significantly	at	10µM	(fig.	S11).		
	
Targeting	PfCLK3	reduces	transmission	to	the	mosquito	vector		
Effects	 of	 PfCLK3	 inhibition	 	 on	 sexual	 stage	 parasites	 was	 tested	 in	 an	 assay	 developed	
using	 the	 P.	 falciparum	 Pf2004	 parasite	 strain	 that	 shows	 high	 levels	 of	 gametocyte	
production	(35).	Importantly,	TCMDC-135051	showed	potent	parasiticidal	activity	in	asexual	
stage	Pf2004	(fig.	S12A)	(pEC50	in	Pf2004	=	6.58	±	0.01	(EC50=0.26µM)	similar	to	that	seen	in	
asexual	 3D7	 and	 Dd2	 parasites.	 In	 addition,	 TCMDC-135051	 showed	 inhibitory	 activity	
between	 commitment	 of	 infected	 red	 blood	 cells	 to	 gametogenesis	 and	 stage	 II	
gametocytes	with	a	pEC50	=	6.04	±	0.11	(EC50=0.91µM)	(fig.	S12B).		
These	in	vitro	studies	were	followed	by	mosquito	membrane	feeding	assays	to	test	directly	
the	impact	of	PfCLK3	inhibition	on	transmission	of	P.	falciparum	to	the	mosquito	vector.	In	
these	 experiments	 stage	 II	 gametocytes	 (from	 3D7	 parasites)	 were	 exposed	 to	 TCMDC-
135051	 and	 allowed	 to	 develop	 to	 stage	 V	 in	 the	 continued	 presence	 of	 drug.	 These	
experiments	 showed	a	 concentration-dependent	 decrease	 in	 stage	V	 gametocyte	number	
(Fig.	5D).	When	analysed	using	a	generalised	linear	mixed	model	(GLMM)	this	effect	had	a	
potency	 of	 EC50=0.8µM	 (Fig.	 5E).	 Furthermore,	 the	 inhibition	 of	 PfCLK3	 significantly	
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decreased	 exflagellation	 (Fig.	 5E,F;	 EC50=0.2µM),	 which	 combined	 with	 the	 effect	 on	
gametocyte	number	contributed	to	a	significant	reduction	 in	transmission	as	measured	by	
the	prevalence	of	oocysts	in	the	gut	of	mosquitoes	in	membrane	feeding	assays	(Fig.	5G,H).		
These	 studies	 were	 further	 extended	 to	 test	 the	 effects	 of	 PfCLK3	 inhibition	 on	 stage	 V	
gametocytes.	While	exposure	of	stage	V	gametocytes	to	TCMDC-135051	for	24	hours	did	
not	 affect	 gametocyte	 number	 (fig.	 S13A,B)	 a	 small	 but	 significant	 reduction	 in	
exflagellation	 (~25%	reduction,	p<2x10-16	as	determined	by	the	GLMM)	was	observed	at	
the	highest	concentration	tested	(fig.	S13C,D).	A	more	pronounced	effect	was	observed	in	
membrane	 feeding	experiments	where	mosquito	 transmission	was	 significantly	 reduced	
by	~50%	(fig.	S13e,f,	p=4.33x10-6).	A	reduction	of	mosquito	infection	prevalence	of	50%	is	
likely	 to	have	a	major	effect	 in	 field	 conditions	where	 infection	 rates	 in	mosquitoes	are	
usually	<5%.	
	
Discussion	
Here	we	 identify	PfCLK3	as	 a	 valid	 and	druggable	anti-malarial	 target	 for	both	 sexual	 and	
asexual	 stages	 of	 parasite	 development	 including	 liver	 stage.	 This	 suggests	 that	 targeting	
PfCLK3	might	not	only	be	a	novel	strategy	for	developing	curative	treatments	for	malaria	by	
clearance	of	asexual	blood	stage	parasites	and	as	a	potential	prophylactic	by	targeting	liver	
stage	but	also	the	parasiticidal	activity	afforded	by	PfCLK3	inhibition	at	gametocytes	would	
indicate	 that	 through	 this	 mechanism	 transmission	 to	 the	 insect	 vector	 could	 also	 be	
affected.	 Since	 splicing	 of	 essential	 transcripts	 occurs	 at	many	 stages	 of	 the	 parasite	 life	
cycle	 it	 is	attractive	to	hypothesise	that	 inhibition	of	PfCLK3,	which	has	been	implicated	in	
the	 phosphorylation	 of	 splicing	 factors	 necessary	 for	 the	 assembly	 and	 activity	 of	 the	
spliceosome		(17,	18,	20),	would	have	a	wide-ranging	impact	on	parasite	viability.	In	support	
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of	 this	 notion	 is	 the	 finding	 that	 PfCLK3	 inhibition	 down-regulated	 over	 400	 essential	
parasite	 transcripts.	 Interestingly,	 the	 majority	 of	 down-regulated	 transcripts	 are	 from	
genes	that	contain	introns	(91%),	providing	further	evidence	that	PfCLK3	is	involved	in	RNA	
splicing	 and	 disruption	 of	 this	 essential	 process	 at	 multiple	 life	 cycle	 stages	 is	 the	 likely	
mechanism	by	which	inhibitors	of	PfCLK3	have	parasiticidal	activity.		
The	 similarity	 of	 CLK3	 orthologues	 in	Plasmodium	 sp.	 suggests	 inhibitors	might	 also	 have	
activity	 across	 a	 number	 of	 Plasmodium	 species.	 This	 was	 confirmed	 here	 by	 almost	
equipotent	 inhibition	 of	 the	 kinase	 activity	 of	 PvCLK3,	 PbCLK3	 and	 PfCLK3	 by	 TCMDC-
135051.	This	in	vitro	action	was	mirrored	by	ex	vivo	activity	in	P.	berghei	and	P.	falciparum	
but	also	P.	knowlesi	(a	model	for	P.	vivax)	indicating	that	inhibition	of	Plasmodium	CLK	might	
have	cross	species	activity.	This	coupled	to	the	reduction	 in	transmission	following	PfCLK3	
inhibition	points	to	PfCLK3	satisfying	many	of	the	criteria	set	by	MMV	for	a	suitable	target	
for	 next	 generation	 anti-malarials;	 namely	 a	 target	 that	 can	 deliver	 rapid,	 multi-stage,	
parasite	killing	across	multiple	species	with	action	as	a	transmission	blocker	(36).		
One	of	 the	major	barriers	associated	with	 the	development	of	protein	kinase	 inhibitors	 is	
the	issue	of	selectivity	since	the	ATP	binding	pocket,	to	which	the	majority	of	protein	kinase	
inhibitors	 bind,	 is	 very	 similar	 between	 protein	 kinases	 (37).	 Here	 TCMDC-135051	 shows	
surprising	selectivity	towards	PfCLK3	even	when	compared	to	its	paralogue	in	P.	falciparum	
PfCLK1	and	the	orthologue	in	human	(PRPF4B)	and	the	closely	related	human	kinase	CLK2.	
Furthermore,	 the	 fact	 that	 our	 transcriptional	 studies	 revealed	 very	 few	off-target	 events	
and	that	adaptive	resistance	and	chemogenetic	resistance	was	associated	with	single	point	
mutations	in	PfCLK3	indicates	that	the	selectivity	of	TCMDC-135051	for	PfCLK3	observed	in	
vitro	was	maintained	in	the	parasite.	The	fact	that	a	hit	from	a	library	screen	can	show	such	
selectivity	 against	 human	 and	 parasite	 kinases	 provides	 encouragement	 that	 PfCLK3	
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selective	 inhibitors	can	be	generated	that	might	provide	therapeutic	efficacy	with	 low	off-
target	toxicity.	
Despite	 the	 fact	 that	 lipid	 kinases	 such	 as	 phosphatidylinositol-4	 kinase	 are	 considered	
promising	 targets	 (38)	 in	 malaria	 and	 the	 abundant	 evidence	 that	 phosphorylation	 and	
phospho-signalling	is	crucial	for	the	viability	of	both	asexual	and	sexual	stages	of	the	malaria	
parasite	 (5,	 8,	 10,	 11)	 together	 with	 reports	 identifying	 essential	 parasite	 protein	 kinase	
targets	(8,	11),	and	the	extensive	experience	of	academic	and	industrial	laboratories	in	the	
design	of	protein	kinase	inhibitor	drugs	(14,	37),	the	targeting	of	parasite	protein	kinases	in	
anti-malarial	 drug	 development	 is	 only	 in	 its	 infancy	 (6,	 39).	 By	 focusing	 on	 an	 essential	
parasite	kinase	and	taking	advantage	of	high	throughput	phenotypic	screens	of	commercial	
and	 academic	 libraries	 (21,	 40,	 41)	 as	 a	 starting	 point	 to	 screen	 for	 inhibitors,	 we	 have	
identified	a	probe	molecule	that	has	not	only	established	the	validity	of	PfCLK3	as	a	target	in	
malaria	 but	 also	 determined	 that	 this	 protein	 kinase	 is	 susceptible	 to	 selective	
pharmacological	inhibition	by	small	drug-like	molecules.	In	this	way,	our	study	lends	weight	
to	 the	 argument	 that	 targeting	 the	 essential	 parasite	 protein	 kinases	 identified	 through	
global	 genomic	 studies	 might	 be	 a	 valid	 therapeutic	 strategy	 in	 the	 development	 of	
molecules	that	meet	many	of	the	criteria	set	for	the	next	generation	of	anti-malarial	drugs.	
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Summary	of	key	materials	and	methods		
(For	full	materials	and	methods	see	supplementary	information)	
High	throughput	Screening	
Compounds	were	 tested	 in	 single	 shot	 at	 10	 µM,	 or	 in	 dose	 response	 from	 100	 µM	 (11-
point,	 3-fold	 serial	 dilutions).	 Screening	 was	 performed	 in	 1536-well	 plates,	 with	 final	
reaction	 and	 read-out	 volumes	of	 4	µL	 and	6	µL,	 respectively.	 The	 results	 from	 the	High-
Throughput	screening	were	further	analysed	using	Activity	Base	(ID	Business	Solutions	Ltd.,	
Surrey,	 UK).	 For	 each	 test	 compound,	 %	 inhibition	 was	 plotted	 against	 compound	
concentration.		
Evolution	of	compound-resistant	lines	and	whole	genome	sequencing	
The	 P.	 falciparum	 Dd2	 strain	 was	 cultured	 in	 triplicate	 in	 the	 presence	 of	 increasing	
concentrations	 of	 TCMDC-135051	 to	 generate	 resistant	 mutants	 as	 previously	
described(42).	 After	 approximately	 60	 days	 of	 selection	 parasites	 were	 cloned	 in	 96-well	
plates	 by	 limiting	 dilution(43).	 The	 half	 maximal	 (50%)	 inhibitory	 concentration	 was	
determined	in	dose-response	format	using	a	SYBR	Green-I	based	cell	proliferation	assay	as	
previously	described(41).	To	determine	genetic	variants	that	arose	during	selection	genomic	
DNA	was	 sequenced	 on	 an	 Illumina	Mi-seq	 and	 single-nulceotide	 variants	 were	 detected	
using	the	Genome	Analysis	Toolkit	(GATK	v1.6).	
Generation	of	G449	mutant	parasite	
Fragment	of	PfCLK3	gene	containing	part	of	exon2,	exon	3,	exon	4	and	part	of	exon	5	(1143	
bp)	 corresponding	 to	 655-1797	 bp	 in	 clk3	 genomic	 sequence	was	 amplified	 using	 primer	
CLK3-HR1	 and	 CLK3-HR2	 and	 the	 amplified	 product	 named	 as	PfCLK3	Homologous	 region	
(CLK3-HR)	was	cloned	in	pHH1	derived	vector	using	restriction	sites	HpaI	and	BglII.	The	rest	
of	 clk3	 gene	 sequence	 down	 stream	 of	 CLK3-HR	 corresponding	 to	 1798-3152	 bp	 Pfclk3	
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genomic	sequence	were	modified	by	removing	introns	and	the	stop	codon	and	the	coding	
sequence	 was	 optimized	 for	 E.coli	 codon	 usage	 to	 make	 it	 dis-similar	 to	 Pfclk3	 genomic	
sequence.	 This	 fragment	 of	 gene	which	we	 named	 as	PfCLK3-codon	 optimized	 (CLK3-CO)	
was	commercially	synthesized	and	included	BglII	recognition	site	at	5’	and	XhoI	recognition	
site	at	3’.	CLK3-CO	was	cloned	downstream	of	CLK3-HR	region	in	the	parent	plasmid	using	
BglII	and	XhoI	restriction	sites	 in	such	a	way	that	the	triple	HA	tag	sequence	in	the	parent	
plasmid	 remained	 in	 frame	 with	 the	 Pfclk3	 sequence.	 The	 BglII	 restriction	 site	 that	 was	
artificially	 introduced	 for	 cloning	 purpose	 was	 mutated	 back	 to	 original	 PfCLK3	 coding	
sequence	 by	 site	 directed	 mutagenesis	 using	 CLK3-BglII-KN1	 and	 CLK3-BglII-KN2	 primers.	
Site	directed	mutagenesis	was	used	again	to	mutate	Glycine	in	PfCLK3	at	position	449	to	an	
alanine.	 The	 targeting	 vector	 generated	 was	 used	 for	 transfection	 of	 schizont	 stage	
parasites.	
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Figure	Legends	
Figure	1.	High-throughput	screen	identifies	inhibitors	to	PfCLK1	and	PfCLK3.		
	(A)	Percent	 Inhibition	distribution	pattern	of	compounds	screened	against	PfCLK3,	binned	
in	5%	intervals.	Active	“hit’	compounds	were	defined	as	those	that	were	positioned	>	3SDs	
from	the	mean.	(B)	Pie-chart	summary	of	the	primary	single	dose	screen.	(C)	Hit	compounds	
were	 used	 in	 concentration	 response	 curves.	 Shown	 is	 a	 comparison	 of	 pIC50	 values	 for	
inhibition	of	PfCLK3	vs	PfCLK1.	TCMDC-135051	(structure	shown)	is	highlighted	as	the	most	
potent	and	selective	PfCLK3	hit.	(D)	The	same	data	as	shown	in	c	but	in	pie	chart	format	of	
compounds	designated	as	inactive,	pan-active	(activity	against	both	PfCLK1	and	PfCLK3),	and	
those	selective	for	either	PfCLK1	or	PfCLK3.		
	
Figure	 2.	 Parasites	 adapted	 to	 become	 less	 sensitive	 to	 TCMDC-135051	 harboured	
mutations	in	the	pfclk3	gene.	
	(A)	 To	generate	TCMDC-135051	 resistant	parasite	 lines	Dd2	parasites	were	 cultured	with	
increasing	concentrations	of	TCMDC-135051	over	a	2	month	period.	This	protocol	resulted	
in	 three	 lines	 that	 were	 less	 sensitive	 to	 TCMDC-135051	 but	 with	 unchanged	 sensitivity	
against	 artemisinin	 (ART)	 and	 chloroquine	 (CQ).	 (B)	 Illustration	 of	 the	 position	 of	 the	
mutations	 in	the	pfclk3	gene	and	pfusp39	gene	 in	the	drug	resistant	mutant	 lines.	 (C)	The	
line	 showing	 the	 greatest	 change	 in	 sensitivity	 to	 TCMDC-135051,	 TM051C,	 expressed	 a	
mutant	form	of	PfCLK3	where	histidine	259	was	substituted	by	a	proline	(illustrated).	Shown	
are	death	curves	for	parental	and	TM051C	lines.	(D)	Enzyme	activity	of	recombinant	PfCLK3	
and	the	H259P	mutant	determined	at	varying	ATP	concentrations	to	derive	a	Km	for	ATP.	(E)	
TCMDC-135051	 kinase	 inhibition	 curves	 for	 PfCLK3	 and	 the	 H259P	 mutant	 at	 Km	 ATP	
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concentrations	 for	 each	 enzyme.	 Data	 presented	 is	 the	 mean	 ±	 S.E.M	 of	 at	 least	 3	
independent	experiments.	
	
Figure	 3.	 Chemogenetic	 validation	 of	PfCLK3	 as	 a	 target	 for	 the	 parasiticidal	 activity	 of	
TCMDC-135051.	
(A)	Schematic	of	the	primary	amino	sequence	of	PfCLK3	showing	the	11	kinase	subdomains	
and	the	amino	acid	sequence	of	subdomain	V	of	PfCLK1	and	PfCLK3.	(B)	Gel	based	assay	of	
the	 phosphorylation	 of	MBP	 by	 PfCLK3	 and	 a	 variant	 where	 glycine	 at	 position	 449	 was	
substituted	 for	 a	 proline	 (G449P).	 The	 top	 gel	 is	 an	 autoradiograph	 and	 the	 bottom	 a	
Coomassie	stain	of	the	same	gel.	(C)	TCMDC-135051	inhibition	of	recombinant	PfCLK3	and	
the	 G449P	 mutant.	 (D)	 Maximal	 kinase	 activity	 of	 recombinant	 PfCLK3	 compared	 to	 the	
activity	of	the	G449P	mutant.	(E)	Schematic	of	gene	targeting	strategy	that	would	result	in	
the	expression	of	the	G449	mutant	(containing	a	triple	HA-tag)	in	place	of	wild	type	PfCLK3.	
(F)	 The	 recombination	 event	 illustrated	 in	 “e”	 was	 identified	 in	 cloned	 G449P	 parasite	
cultures	 by	 PCR	 (A3	 and	 A8).	 (G)	 Expression	 of	 the	 triple	 HA-tagged	 G449P	 mutant	 in	
genetically	engineered	parasite	cultures	(G449P)	was	determined	by	Western	blotting.	Gel	
on	the	left	probed	lysates	with	anti-HA	antibodies,	in	the	middle	is	a	loading	control	probed	
with	 anti-PfCDPK1	 antibodies	 and	 on	 the	 right	 is	 a	 Coomassie	 stain	 of	 the	 lysate	
preparations	used	in	the	Western	blots.	(H)	The	growth	inhibition	curves	of	TCMDC-135051	
against	 parent	 3D7	 parasites	 and	 G449P	 parasites	 (A3	 and	 A8).	 The	 data	 shown	 in	 the	
graphs	are	the	mean	±S.E.M	of	at	least	three	independent	experiments.	*p<0.05	t-test.		
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Figure	4.	Inhibition	of	PfCLK3	prevents	trophozoite	to	schizont	transient,	kills	the	parasite	
with	rapid	kinetics	and	disrupts	gene	transcription	
(A)	 Smears	 of	 synchronised	 blood	 stage	 P.	 falciparum	 cultures	 following	 treatment	 with	
TCMDC-135051	 (2µM)	 were	 taken	 at	 the	 indicated	 times	 after	 TCMDC-135051	
administration.	 (B)	 The	 in	 vitro	 parasite	 reduction	 rate	 in	 the	 presence	 of	 10	 x	 EC50	 of	
TCMDC-135051	 was	 used	 to	 determine	 the	 onset	 of	 action	 and	 rate	 of	 killing.	 The	 data	
presented	represents	the	mean	±S.E.M.	Previous	results	reported	on	standard	anti-malarials	
tested	 at	 10	 ×	 EC50	 using	 the	 same	 conditions	 are	 shown	 for	 comparison	 (44).	 (C,D)	
Illustration	of	the	genes	that	are	designated	as	significantly	changing	(Moderate	t	test	n=4)	
in	transcription	following	treatment	with	TCMDC-135051	(1µM,	60	mins)	of	either	(c)	parent	
Dd2	parasites	or	(D)	TM051C	mutant	parasites.	Each	line	represents	the	log2	fold	change	in	
the	probes	used	 in	 the	micro-array.	 The	number	of	 genes	 represented	by	 the	probes	 are	
indicated.	 	 (E)	 Summary	 of	 the	 parasite	 processes	 associated	 with	 the	 genes	 where	
transcription	 is	 significantly	 down-regulated	 	 following	 TCMDC-135051	 treatment.	 (F)	
Assessment	 of	 intron	 containing	 genes	 among	 genes	 that	 are	 up-regulated	 and	 down-
regulated	 in	 Dd2	 parasites	 following	 TCMDC-135051	 treatment.	 (G)	Assessment	 of	 intron	
containing	genes	in	the	plasmodium	genome	(data	derived	from	Plasmodb).	
	
Figure	5.	Inhibition	of	PfCLK3	has	parasiticidal	activity	at	multiple	parasite	species,	shows	
in	 vivo	 parasiticidal	 activity	 in	P.	 berghei,	 blocks	 gametocyte	 development	 and	 reduces	
transmission	to	the	mosquito	vector.	
Concentration	 effect	 curve	 of	 TCMDC-135051	 on	 blood	 stage	 (A)	 P.	 knowlesi	 and	 (B)	 P.	
berghei	parasites.	(C)	TCMDC-135051	P.	berghei	in	vivo	growth	inhibition	curves	and	Day	4	
percentage	 suppression	 plots	 (insert).	 Error	 bars	 are	 standard	 deviations	 from	 n=4	 mice	
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groups.	Statistical	comparisons	between	drug	treated	and	vehicle	are	shown	using	the	one	
way	ANOVA	and	Dunnett's	multiple	comparisons	test.	****	p	<0.0001.	(D-H)	Concentration-
effect	of	exposure	of	stage	II-V	P.	falciparum	(clone	3D7)	gametocytes	to	TCDMDC-135051	
on	 (D,E)	 gametocyte	 (GC)	 numbers	 in	 culture,	 (E,F)	 exflagellation,	 and	 (G,H)	 prevalence	
(number	of	mosquitoes	with	oocyst	infection	/	number	of	mosquitoes	dissected)	
	of	 infection	 of	 An.	 coluzzii	 mosquitoes.	 Graphs	 (D,E,F)	 show	 the	 mean	 ±SEM	 of	 4	
independent	experiments.	Panels	(E,F,H)	show	the	predicted	effects	of	drug	concentrations	
according	to	the	maximal	GLMM	with	the	shaded	area	indicating	95%	confidence	intervals.	
From	the	GLMM	analysis	the	approximate	EC50	values	were	calculated.	
	
Table	 1:	 Adaptive	 resistance	 to	 TCMDC-135051.	 Dd2	 parasites	 were	 exposed	 to	 sub-
threshold	concentrations	of	TMDC-135051	and	three	lines	isolated	that	were	less	sensitive	
to	 TCMDC-135051	 but	 with	 unchanged	 sensitivity	 to	 artemisinin	 (ART)	 and	 chloroquine	
(CQ).	Shown	are	nucleotide	changes	and	associated	amino	acid	changes	in	genes	from	the	
resistance	 lines	 as	well	 as	 the	 identity	 and	 annotated	 function	 of	 the	mutant	 genes.	 IC50	
values	 associated	 with	 each	 line	 for	 ART,	 CQ	 and	 TCMDC-135051	 together	 with	 the	 fold	
change	in	IC50	for	TCMDC-135051	compared	to	Dd2	parent	parasites	are	shown.	Data	is	the	
mean	±	S.E.M	of	three	experiments.			
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Summary	
Introduction	
Despite	the	positive	effects	of		intervention	strategies	that	include	insecticide	impregnated	
bed	nets	and	artemisinin-based	drug	therapies	malaria	still	kills	nearly	0.5	million	people	a	
year	 and	 infects	 over	 200	 million	 individuals	 globally.	 This	 together	 with	 the	 emerging	
resistance	of	the	parasite	to	frontline	anti-malarials	means	that	there	is	an	urgent	need	for	
novel	treatments	that	not	only	offer	a	cure	for	malaria	but	that	also	prevent	transmission.	
Here	we	show	that	by	inhibition	of	an	essential	protein	kinase	that	is	a	key	regulator	of	RNA	
processing	we	are	able	to	kill	the	parasite	in	the	blood	and	liver	stages	as	well	as	prevent	the	
development	 of	 the	 sexual	 stage	 gametocytes	 thereby	 blocking	 transmission	 to	 the	
mosquito.		
Rationale	
Our	group	have	previously	published	a	list	of	36	protein	kinases	that	are	essential	for	blood	
stage	 survival	 of	 the	 most	 virulent	 form	 of	 the	 human	 malaria	 parasite,	 Plasmodium	
falciparum.	 Here	 we	 focus	 on	 one	 of	 these	 protein	 kinases,	 PfCLK3,	 and	 reason	 that	
inhibition	of	 this	protein	kinase	by	a	 small	drug-like	molecule	would	be	effective	at	killing	
blood	 stage	parasites.	We	 further	hypothesised	 that	 since	PfCLK3	plays	a	 key	 role	 in	RNA	
splicing	that	 inhibition	of	 this	kinase	would	be	effective	at	killing	the	parasite	all	 stages	of	
the	 life	 cycle	 where	 RNA	 splicing	 is	 required.	 This	 would	 include	 blood,	 liver	 and	 sexual	
stages.				
Results	
By	screening	a	focused	library	of	nearly	30,000	compounds	we	identified	a	probe	molecule	
that	 selectively	 inhibited	 PfCLK3	 and	 that	 killed	 blood	 stage	 P.	 falciparum.	 Using	 a	
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combination	 of	 evolved	 resistance	 and	 chemogenetics	 we	 established	 that	 our	 probe	
molecule	 had	 parasiticidal	 activity	 by	 inhibition	 of	 PfCLK3.	We	 further	 demonstrated	 that	
inhibition	of	PfCLK3	in	parasites	resulted	in	a	reduction	in	over	400	gene	transcripts	known	
to	 be	 essential	 for	 parasite	 survival.	 The	 fact	 that	 the	 vast	 majority	 of	 the	 genes	 down-
regulated	 by	 PfCLK3	 inhibition	 contained	 introns	 supported	 the	 notion	 that	 inhibition	 of	
PfCLK3	 killed	 the	 malaria	 parasite	 by	 preventing	 the	 splicing	 of	 essential	 parasite	 genes.	
Since	there	is	a	high	degree	of	homology	between	orthologues	of	CLK3	in	other	Plasmodium	
species	(Plasmodium	spp)	it	might	be	expected	that	our	probe	molecule	would	both	inhibit	
CLK	 contained	 in	other	malaria	parasite	 species	 and	have	effective	parasiticidal	 activity	 in	
these	parasites.	 This	was	 indeed	 found	 to	be	 the	 case	with	our	molecule	 showing	potent	
inhibition	 of	 CLK3	 from	 P.	 vivax	 and	 P.	 berghei	 as	 well	 as	 killing	 the	 blood	 stages	 of	 P.	
berghei	and	P.	knowlesi.	Finally,	we	demonstrated	that	PfCLK3	inhibition	also	kills	liver	stage	
P.	falciparum	parasites	and	importantly	prevents	the	development	of	gametocytes	thereby	
blocking	the	infection	of	mosquitoes.	
Conclusion	
We	show	that	inhibition	of	the	essential	malaria	protein	kinase	CLK3	can	kill	multiple	species	
of	 malaria	 parasites	 at	 the	 blood	 stage	 as	 wells	 as	 killing	 liver	 stage	 P.	 falciparum	 and	
blocking	 transmission	 of	 the	 parasite	 to	 the	 mosquitoes	 by	 preventing	 gametocyte	
development.	 In	 this	 way	 we	 validate	 Plasmodium	 spp	 CLK3	 as	 a	 target	 that	 can	 offer	
prophylactic,	curative	and	transmission	blocking		potential.	
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Caption	for	cover	figure	
A	new	drug	target	for	malaria.	Inhibition	of	the	malaria	parasite	protein	kinase,	PfCLK3,	kills	
blood	 stage	 parasites	 and	 stops	 the	 parasite	 infecting	 mosquitoes.	 In	 this	 way	 PfCLK3	 is	
validated	 as	 a	 curative	 and	 transmission	 blocking	 drug	 target	 in	 malaria.	 Shown	 is	 an	
infected	human	 red	blood	cell	under	 control	 conditions	 (left)	and	where	PfCLK3	has	been	
inhibited	(right)	by	the	selective	PfCLK3	inhibitor	shown.	
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Supplementary	Materials	and	Methods	
In	vitro	Kinase	Activities	and	Inhibition	Assay	
Kinase	assays	were	carried	in	kinase	buffer	containing	(20	mM	HEPES,	pH	7.4,	10	mM	MgCl2,	
1	mM	DTT,	50	µM	adenosine	triphosphate	(ATP),	0.1	MBq	[γ-32P]-ATP)	using	0.5	µg	purified	
His-tagged	 recombinant	 protein	 kinases.	 Protein	 kinases	 were	 incubated	 with	 exogenous	
substrate,	Histone	Type	 IIA	2	µg;	Myelin	Basic	Protein	 (MBP)	2	µg;	 and	α-Casein	2	µg;	or	
with	a	PBS	as	a	negative	control	for	30	minutes	at	37°C.		
The	reactions	were	stopped	by	adding	equal	volume	of	2X	Laemmli	buffer	after	incubation	
and	boiled	for	2	minutes	at	60°C.	Samples	were	separated	on	15%	SDS-PAGE,	stained	with	
Coomassie	Brilliant	Blue	and	dried	by	means	of	vacuum	gel	drying.	Dried	gels	were	exposed	
to	X-ray	film	at	-80°C	and	autoradiographs	were	collected.		
For	 in	 vitro	 inhibition	 assays,	 compounds	 (e.g.	 TCMDC-135051)	 was	 added	 to	 a	 final	
concentration	as	 indicated.	For	 control,	a	no	 inhibitor	 reaction	 tube	was	 setup	 to	exclude	
any	 other	 unknown	 inhibitory	 effect.	 All	 other	 reaction	 conditions	 remained	 the	 same.	
Quantification	of	activity	was	carried	out	using	ImageJ	(1.49v).	
Time	Resolve	Florescence	Energy	Transfer	(TR-FRET)		
Biochemical	kinase	assays	were	carried	out	using	time-resolved	florescence	energy	transfer	
(TR-FRET)	to	determine	kinase	activity,	Km	for	ATP	and	IC50	values	for	the	respective	kinases	
used.	TR-FRET	reactions	were	performed	using	the	appropriate	amount	of	kinase	(5nM	for	
PfCLK1	and	50	nM	for	PfCLK3	and	G449P)	 in	a	kinase	buffer	(containing	50	mM	HEPES,	10	
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mM	MgCl2,	2	mM	DTT,	0.1%	Tween-20,	and	1	mM	EGTA),	ULight-labeled	peptide	substrate	
(MBP	peptide	or	CREPtide)	and	an	appropriate	europium-labeled	anti-phospho	antibody	in	
two	steps.		
First,	in	a	10	µL	reaction	volume	5	μL	of	2X-required	enzyme	concentration	and	5μL	of	2X-
required	substrate	mix	and	cold	ATP	were	incubated	in	a	384	well	plate	at	37°C	for	1	hour.	
Second,	following	incubation,	adding	30	mM	EDTA	in	1X	Lance	detection	buffer	containing	
3nM	Europium-labeled	anti-phospho	specific	antibody	 incubated	at	 room	temperature	 for	
1-hour	to	stop	the	reaction	and	enhance	detection	and	this	is	then	read	using	the	ClarioStar.		
Kinase	 substrate	 phosphorylation	 results	 in	 the	 Europium-labeled	 anti-phospho	 specific	
antibody	 recognizing	 the	 phosphorylated	 site	 on	 the	 substrate.	 The	 Europium	 donor	
fluorophore	is	excited	at	320	or	340	nm	and	energy	is	transferred	to	the	ULight	acceptor	dye	
on	the	substrate,	which	finally	results	in	the	emission	of	light	at	665	nm.	The	level	of	ULight	
peptide	phosphorylation	determines	the	intensity	of	the	emission.		
To	 test	 for	 inhibition	 by	 small	 molecules	 such	 as	 TCMDC-135051,	 serial	 dilution	 of	 the	
inhibitor	(made	at	4	times	the	required	concentration)	was	made	and	added	to	the	protein	
mixture	 before	 adding	 the	 substrate	 mix	 at	 4X	 the	 required	 concentration.	 For	
normalization,	 a	 no	 kinase	 and	 a	 no	 inhibitor	 reaction	 wells	 were	 included	 and	 all	
experiments	were	run	in	triplicate.			
Expression	and	purification	of	PfCLKs,	PfCDPK1	and	PfPKG	
Gene	 encoding	 the	 kinase	 domain	 of	 PfCLK1	 (residues	 534-857)	 was	 amplified	 using	 P.	
falciparum	 (3D7)	 genomic	 DNA	 primers	 CLK1-FamB1	 and	 CLK1-FamB2	 .	 The	 amplified	
product	was	 cloned	 in	 plasmid	 pLEICS-05	 (University	 of	 Leicester)	 as	 has	 been	 previously	
	 39	
described	for	cloning	of	PfCLK3	(5).	Plasmids	encoding	the	kinase	domain	of	PfCLK1	(pLEICS-
05_PfCLK1	(residues	534-875-5xHIS))	and	full	 length	PfCLK3	(pLEICS-05_PfCLK3	(residues-1-
669-5xHIS))	were	used	to	transform	BL21	Codon	Plus	(DE3)	Escherichia	coli	competent	cells	
(Agilent	Technologies).	Protein	expressions	were	induced	for	4	hours	at	37°C	for	PfCLK3	and	
at	 22°C	 for	 PfCLK1	 after	 the	 addition	 of	 0.1	 mM	 isopropyl	 β-D-1-thiogalactopyranoside	
(IPTG).	Cell	pellets	were	lysed	by	sonication	in	Lysis	Buffer	(20	mM	Tris/HCl,	pH	8.0,	300	mM	
NaCl,	1	mM	DTT	and	10	mM	Imidazole)	and	EDTA-free	protease	inhibitor	cocktail,	followed	
by	 centrifugation	 at	 8000	 g.	 Clarified	 supernatants	 were	 loaded	 onto	 Ni-NTA	 Superflow	
cartridges	 (Qiagen),	 washed	 using	 lysis	 buffer,	 and	 eluted	 with	 lysis	 buffer	 containing	
300mM	 Imidazole.	Protein	was	dialysed	 in	buffer	 containing	20	mM	Tris/HCl,	pH	7.4,	150	
mM	NaCl,	1	mM	MgCl2	and	10%	glycerol		and	aliquots	were	stored	at	-80°C.	
Expression	and	purification	of	PfCDPK1	and	PfPKG	recombinant	proteins	was	conducted	as	
described	previously	(5).	
	
Kinase	assay	optimisation	for	high	throughput	screen		
Enzyme	kinase	assays	were	conducted	in	10µL	reaction	volume	at	room	temperature	for	1	
hour	in	buffer	containing	50	mM	HEPES	pH	7.5,	10	mM	MgCl2,	1	mM	EGTA,	2	mM	DTT	and	
0.01%	 Tween20	 in	 a	 black	 384-well	 microplates	 (Greiner	 Bio-One).	 ULightTM	 substrates,	
Europium	 labelled	anti-phospho-ULightTM,	and	10X	Detection	Buffer	were	purchased	 from	
Perkin	 Elmer.	 ULight-CREBtide	 (Sequence:	 CKRREILSRRPSYRK)	 and	 ULight-MBP	 peptide	
(sequence:	 CFFKNIVTPRTPPPSQGK)	 were	 the	 substrates	 of	 choice	 for	 PfCLK1	 and	 PfCLK3,	
respectively.	To	determine	Km	ATP,	Serial	dilutions	of	ATP	from	1000	or	500	µM	were	added	
to	 the	 reaction	wells	 containing	PfCLK1	+	ULight-CREBtide	or	PfCLK3	+	ULight-MBP	 in	384	
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well	 black	 microplates	 (Greiner	 Bio-One).	 End	 point	 665/615	 nm	 data	 were	 fit	 to	 the	
Michaelis-Menten	equation	using	GraFit	version	5.0.12	(Erithacus	Software	Ltd.)		
Reactions	 were	 performed	 using	 ATP	 at	 Km	 concentration	 and	 optimized	 ULightTM	 and	
kinase	 concentrations	 (30	 µM	 ATP	with	 5nM	 PfCLK1	 and	 10µM	 ATP	with	 50nM	 PfCLK3).	
Kinase	reactions	were	stopped	by	addition	of	the	Detection	Mix	Solution	containing	10	mM	
EDTA	 and	 1	 mM	 anti-phospho-ULightTM	 in	 1X	 Detection	 Buffer	 and	 the	 TR-FRET	 signal	
(emission1	=	665	nm,	emission2	=	615	nm)	was	acquired	after	1-8	hours	using	an	EnVisionTM	
Multilabel	plate	reader	(Perkin	Elmer,	Waltham,	MA).	
Miniaturization	to	1536-well	format	was	possible	and	final	assay	performance	was	assessed	
by	 calculation	 of	 means	 and	 standard	 deviation	 of	 standard	 inhibition	 curves.	 Signal-to-
background	ratios	S/B	of	10	and	5	and	Z´-values	of	0.8	and	0.6	were	calculated	for	PfCLK1	
and	PfCLK3,	respectively,	suitable	for	HTS.		
	
High	throughput	Screening	
GSK	 compounds	 from	 the	 Tres	 Cantos	 Antimalarial	 Set	 (TCAMS,	 13194	 compounds),	 and	
Protein	 Kinase	 Inhibitor	 Set	 displaying	 known	 anti-plasmodial	 activity	 (PKIS,	 1115	
compounds),	and	MRC-Technology	index	library	(MRCT,	9970	compounds)	were	screened	in	
single	 shot	 against	 PfCLK1	 and	 PfCLK3.	 Kinase	 inhibitor-like	 compounds	 from	 the	 MMV	
Malaria	 Box	 (a	 selection	 of	 260	 from	 the	 original	 400	 compound	 library)	 were	 screened	
against	PfCLK1	and	PfCLK3	in	dose	response	experiments	(n=2),	together	with	hits	obtained	
from	the	Single	Shot	Screen.	
Compounds	were	 tested	 in	 single	 shot	 at	 10	 µM,	 or	 in	 dose	 response	 from	 100	 µM	 (11-
point,	 3-fold	 serial	 dilutions).	 Screening	 was	 performed	 in	 1536-well	 plates,	 with	 final	
reaction	and	read-out	volumes	of	4	µL	and	6	µL,	respectively.	
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40	 nL	 of	 100x	 compound,	 or	 40	 nL	 DMSO	 (columns	 11&12	 -	 maximum	 and	 35&36	 -	
minimum	activity	 controls)	were	dispensed	onto	each	plate	using	an	Echo	Liquid	handler.	
2µL	of	 2x	PfCLK	or	 kinase	buffer	were	 added	onto	 all	 plates	 except	 columns	35	&	36	 (no	
enzyme,	minimum	activity	control),	where	2	µL	of	kinase	buffer	were	added.	Reactions	were	
initiated	 upon	 addition	 of	 2x	 Substrate	 Solution	 containing	 Km	 ATP	 concentration	 and	
ULight-MBP	 or	 ULight-CREBtide	 for	 PfCLK3	 and	 PfCLK1,	 respectively.	 	 Solutions	 were	
dispensed	with	a	Multidrop	Combi	 (Thermo	Fisher	 Scientific,	Waltham,	MA,	USA)	and	TR-
FRET	readouts	were	collected	using	an	EnVisionTM	multilabel	plate	reader	(Perkin	Elmer)	and	
normalized	to	control	values	of	uninhibited	and	no	enzyme.	
The	results	 from	the	High-Throughput	screening	were	further	analysed	using	Activity	Base	
(ID	Business	Solutions	Ltd.,	Surrey,	UK).	For	each	test	compound,	%	 inhibition	was	plotted	
against	compound	concentration.	To	calculate	 IC50,	data	was	fit	to	the	standard	single-site	
four-parameter	logistic	equation:	
y	=	{(Ymax	–	Ymin)/[1	+	([I]	/	IC50)^n]}	+Ymin		
Where,	 Ymax	 is	 the	 maximum	 response,	 Ymin	 is	 the	 baseline,	 [I]	 is	 the	 concentration	 of	
compound,	n	is	the	Hill	slope,	IC50	is	the	inflection	point	concentration.	In	cases	where	the	
highest	concentration	tested	(i.e.,	100	μM)	did	not	result	in	greater	than	50%	inhibition,	the	
IC50	was	determined	as	 greater	 than	100	μM.	pIC50=	 -logIC50,	 expressing	 the	 IC50	 in	molar	
units.	
	
Parasite	culture	
P.	 falciparum	 cultures	 were	 maintained	 in	 RPMI-1640	 media	 (Invitrogen)	 supplemented	
with	0.2%	sodium	bicarbonate,	0.5%	Albumax	II,	2.0	mM	L-glutamine	(Sigma)	and	10	mg/L	
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gentamycin.	Human	blood	group	O,	Rh	+ve	were	used	for	parasite	culture	and	cultures	were	
maintained	at	5%	carbon	dioxide,	5%	oxygen	and	90%	nitrogen	mixed	gas	incubator	at	37oC.	
P.	knowlesi	A1-H.1	parasites	were	maintained	in	RPMI-1640	media	supplemented	with	0.2%	
sodium	bicarbonate,	10%	horse	 serum	 (Gibco),	0.5%	Albumax	 II	 ,	2.0	mM	L-glutamine,	10	
mg/L	gentamicin.	Schizont	enrichment	was	performed	via	centrifugation	at	900	x	g	 for	12	
minutes	 by	 layering	 the	 parasite	 culture	 on	 top	 of	 a	 55%	 (v/v)	 Nycodenz	 (Axis	 Shield)	
cushion	diluted	from	a	27.6%	Nycodenz	(wt/vol)	stock	solution	in	10	mM	HEPES,	pH	7.4.	For	
drug	assays,	schizonts	enriched	from	a	semi-synchronous	culture	were	added	to	fresh	RBCs	
and	adjusted	to	a	0.5%	parasitaemia	following	reinvasion.	
	
Evolution	of	compound-resistant	lines	and	whole	genome	sequencing	
The	 P.	 falciparum	 Dd2	 strain	 was	 cultured	 in	 triplicate	 in	 the	 presence	 of	 increasing	
concentrations	 of	 TCMDC-135051	 to	 generate	 resistant	 mutants	 as	 previously	
described(42).	 After	 approximately	 60	 days	 of	 selection	 parasites	 were	 cloned	 in	 96-well	
plates	 by	 limiting	 dilution(43).	 The	 half	 maximal	 (50%)	 inhibitory	 concentration	 was	
determined	in	dose-response	format	using	a	SYBR	Green-I	based	cell	proliferation	assay	as	
previously	described(41).	To	determine	genetic	variants	that	arose	during	selection	genomic	
DNA	was	 isolated	 from	each	parasite	 strain.	 250	base	pair	 paired-end	DNA	 libraries	were	
prepared	 using	 the	 Illumina	 Nextera-XT	 method	 and	 sequenced	 on	 an	 Illumina	 Mi-seq	
according	 to	 manufacturer’s	 instructions.	 Reads	 were	 aligned	 to	 the	 P.	 falciparum	 3D7	
reference	genome	 (PlasmoDB	v9.0)	 as	previously	described(45).	 Single-nulceotide	variants	
were	detected	using	the	Genome	Analysis	Toolkit	(GATK	v1.6)	and	the	filtered	based	on	the	
distribution	of	each	quality	control	parameter	(QD	<	15.0,	SQR	>	1.9,	MQ	<	50.0,	DP	>	2700,	
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MQRankSum	-11.3	<	x	<	11.3,	Qual	>	400,	DP	>	6,	GQ	>	15.0,	ReadPosRankSum	-12.3	<	x	<	
12.3,	snp	cluster:	3	in	a	window	of	10.		
	
Blood	stage	development	inhibition	assay	by	microscopy	
Parasite	cultures	were	tightly	synchronized	by	two	Percoll	treatments	in	a	span	of	one	hour	
followed	by	 sorbitol	 treatment	 to	 remove	any	 left	over	 schizonts	after	 the	 second	Percoll	
treatment	and	the	very	early	ring	stage	parasites	(0-1	Hour)	were	collected	which	were	used	
to	monitor	inhibition	of	blood	stage	development	of	the	parasite	following	treatment	with	
inhibitor.	 Synchronized	 parasite	 cultures	were	 treated	with	 1	µM	TCMDC-135051	 at	 time	
point	0,	10,	20,	30	and	40	hours	and	thin	smears	from	each	treatment	or	no	treatment	were	
prepared	at	 time	point	0	hour,	10	hour,	20	hour,	30	hour,	40	hour,	50	hour	and	70	hour.	
Thin	 smears	were	 stained	with	Giemsa’s	 stain	 and	 images	of	 the	parasites	were	 acquired	
under	 light	microscope	 at	 100X	magnification	 to	 study	 the	 stages	 of	 parasite	 blood	 stage	
development	affected	by	the	inhibition	of	PfCLK3.	
	
Asexual	EC50	determination	
Early	 ring	 stages	 of	 P.	 falciparum	 cultures	 were	 plated	 in	 96-well	 black	 plate	 with	 clear	
bottom	at	2	%	hematocrite	and	0.3	%	parasitaemia.	Serial	dilations	of	compound	TCMDC-
135051	staring	at	maximum	100	µM	final	concentrations	were	added	to	the	parasite	culture	
in	triplicate	and	three	wells	were	included	with	no	drugs	as	control.	Parasite	cultures	were	
incubated	 at	 37°C	 for	 72	 hours	 and	 the	 viability	 of	 parasites	 in	 each	 condition	 were	
measured	 by	 staining	 parasite	 nuclei	 with	 nucleic	 acid	 stain	 SYBR	 Green	 (Invitrogen).	
Excitations	 at	 green	 channel	were	 acquired	 on	 ClarioStar	 and	 the	 data	were	 analyzed	 by	
Prism	software.	
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Parasite	reduction	rate	assay	
Ring	stages	of	3D7	parasite	clone	were	treated	with	TCMDC-135051	corresponding	to	10X	
EC50	of	the	inhibitor	concentration	at	blood	stage	development	inhibition	assay	(EC50-188nM	
using	hypoxanthine	incorporation	assay).	Parasite	cultures	were	treated	for	120	hours	with	
drug	being	renewed	every	24	hour	during	the	treatment.	Samples	of	drug	treated	parasites	
were	 collected	 every	 24-hour	 (24,	 48,	 72,	 96	 and	 120	 hour	 time	 points)	 and	 drug	 was	
washed	 from	 the	 collected	 sample	 by	 two	 rounds	 of	 centrifugation.	 Drug	 free	 parasites	
were	 diluted	 by	 three	 fold	 limiting	 dilution	 and	 cultured	 for	 28	 days	 in	microtitre	 plates.	
These	experiments	were	repeated	four	times	(n=4).	Samples	were	collected	on	21	day	and	
28	 day	 from	 the	 microtitre	 plate	 and	 parasite	 viability	 assessed	 by	 hypoxanthine	
incorporation	 assay.	 For	 the	 hypoxanthine	 incorporation	 assay,	 100µl	 of	 parasite	 cultures	
were	supplemented	with	8	µl	of	0.025mci/ml	3H-hypoxanthine	and	parasite	cultures	were	
maintained	 for	 72	 hours	 and	 incorporation	 of	 3H-hypoxanthine	 measured	 by	 counting	
radioactivity	in	each	well.	Treatment	with	pyrimethamine	was	also	conducted	in	parallel	as	
control	 and	 previous	 data	 for	 artemisnin,	 atovaquone	 and	 chloroquine	 were	 included	 to	
allow	comparative	analysis	of	the	killing	profile.	
	
Generation	of	G449	mutant	parasite	
Fragment	of	PfCLK3	gene	containing	part	of	exon2,	exon	3,	exon	4	and	part	of	exon	5	(1143	
bp)	 corresponding	 to	 655-1797	 bp	 in	 clk3	 genomic	 sequence	was	 amplified	 using	 primer	
CLK3-HR1	 and	 CLK3-HR2	 and	 the	 amplified	 product	 named	 as	PfCLK3	Homologous	 region	
(CLK3-HR)	was	cloned	in	pHH1	derived	vector	using	restriction	sites	HpaI	and	BglII.	The	rest	
of	 clk3	 gene	 sequence	 down	 stream	 of	 CLK3-HR	 corresponding	 to	 1798-3152	 bp	 Pfclk3	
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genomic	sequence	were	modified	by	removing	introns	and	the	stop	codon	and	the	coding	
sequence	 was	 optimized	 for	 E.coli	 codon	 usage	 to	 make	 it	 dis-similar	 to	 Pfclk3	 genomic	
sequence.	 This	 fragment	 of	 gene	which	we	 named	 as	PfCLK3-codon	 optimized	 (CLK3-CO)	
was	commercially	synthesized	and	included	BglII	recognition	site	at	5’	and	XhoI	recognition	
site	at	3’.	CLK3-CO	was	cloned	downstream	of	CLK3-HR	region	in	the	parent	plasmid	using	
BglII	and	XhoI	restriction	sites	 in	such	a	way	that	the	triple	HA	tag	sequence	in	the	parent	
plasmid	 remained	 in	 frame	 with	 the	 Pfclk3	 sequence.	 The	 BglII	 restriction	 site	 that	 was	
artificially	 introduced	 for	 cloning	 purpose	 was	 mutated	 back	 to	 original	 PfCLK3	 coding	
sequence	 by	 site	 directed	 mutagenesis	 using	 CLK3-BglII-KN1	 and	 CLK3-BglII-KN2	 primers.	
Site	directed	mutagenesis	was	used	again	to	mutate	Glycine	in	PfCLK3	at	position	449	to	an	
alanine	residue	using	CLK3-G449P1	and	CLK3-G449P2	primers.	The	target	vector	generated	
was	 sequenced	 to	 confirm	 the	 desired	 sequence	 of	 Pfclk3	 in	 the	 plasmid	 and	 further	
confirmed	 that	3-HA	sequence	 is	 in	 frame	with	clk3	coding	 sequence.	10	µg	of	 the	 target	
vector	was	used	for	transfection	of	schizont	stage	of	the	parasite	using	Lonza	nucleofactor	
following	the	protocol	as	has	been	published	by	 (45).	Transfected	parasites	were	cultured	
under	 selection	 drug	 pressure	 (2.5nM	WR99210)	 till	 ring	 stage	 of	 the	 parasites	 could	 be	
seen	in	Giemsa	stained	smear.	The	parasites	were	maintained	under	drug	OFF	(three	weeks)	
and	 drug	 ON	 (three	 weeks)	 pressure	 for	 two	 cycles	 to	 eliminate	 the	 parasite	 where	 the	
target	 plasmid	 was	 maintained	 episomally.	 Following	 drug	 cycle	 clones	 of	 parasite	 were	
generated	by	 limiting	dilution	and	 the	 integration	of	 target	plasmid	at	 the	Pfclk3	genomic	
locus	of	the	cloned	parasite	was	confirmed	by	PCR	amplification	of	1493	bp	gene	fragment	
using	primers	P3	(448-478	bp	 in	Pfclk3	genomic	 locus,	upstream	of	PfCLK3-HR	region)	and	
P4	 (1923-1940	bp	sequence	 in	clk3	gene	of	 transgenic	parasite,	part	of	CLK3-CO	region	 in	
target	plasmid)	which	could	be	generated	only	if	the	target	plasmid	is	integrated	at	the	clk3	
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genomic	 locus.	 At	 the	 same	 time	 PCR	 amplification	 using	 primers	 P1	 (571-605	 bp	 in	 clk3	
genomic	locus,	upstream	of	CLK3-HR	region)	and	P2	(1825-1852	bp	in	Pfclk3	genomic	locus,	
in	 a	 region	 which	 is	 replaced	 by	 CLK3-CO	 region	 in	 transgenic	 parasite)	 did	 not	 show	
amplification	 in	CLK3-G449P	clones	 (A3	and	A8),	which	 confirms	 that	 the	wild	 type	Pfclk3	
locus	 was	 destroyed	 in	 the	 transgenic	 parasites.	 Amplification	 of	 1282	 bp	 product	 using	
primer	P1	and	P2	confirms	that	these	primers	can	amplify	clk3	at	genomic	locus	of	wild	type	
3D7	parasites.	
	
Western	blotting	
Parasite	 lysate	from	3D7	wild	type	parasite	and	two	CLK3-G449P	clones	(A3	and	A8)	using	
lysis	 buffer	 containing	 20	 mM	 Tris	 pH-8.0,	 150	 mM	 sodium	 chloride	 (NaCl),	 1	 mM	 di-
thiotritol,	1	mM	ethylenediaminetetraacetic	acid	 (EDTA),	1%	 IGEPAL	CA630	detergent	and	
protease	and	phosphatase	inhibitor	mix.	Parasite	 lysates	were	cleared	by	centrifugation	at	
21000xg	for	5	minutes	and	20	µg	of	parasite	 lysate	were	separated	on	8%	polyacrylamide	
gel	under	reducing	condition.	Proteins	were	transferred	to	nitrocellulose	membrane	and	the	
membranes	were	blocked	for	two	hour	with	blocking	buffer	that	contain	20	mM	Tris	pH	7.4,	
150mM	NaCl,	 0.1%	 Tween-20	 and	 5%	 skimmed	milk.	 Following	 blocking	 the	membranes	
were	 incubated	 with	 primary	 antibodies	 (Anti-HA	 monoclonal	 antibody	 or	 anti-PfCDPK1	
polyclonal	 antibody)	 at	 1:1000	 dilution	 in	 blocking	 buffer	 for	 one	 hour.	 The	 membranes	
were	 washed	 four	 times,	 each	 of	 15	minutes,	 with	 wash	 buffer	 (blocking	 buffer	 without	
milk)	 and	 incubated	 with	 goat	 anti-rat	 HRP	 conjugated	 antibody	 at	 1:2000	 dilution	 in	
blocking	buffer	 for	one	hour.	 Following	 this	 incubation	 the	blots	were	washed	 four	 times	
with	wash	buffer	and	developed	using	enhanced	chemi-luminiscence	kit.	The	luminescences	
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from	the	blots	were	acquired	on	X-ray	 film.	The	control	gel	 following	electrophoresis	was	
stained	with	Coomassie	stain	to	show	equal	loading.	
	
DNA	Microarray	experiment	
Microarray	was	used	to	study	changes	in	transcript	level	in	the	parasite	following	treatment	
with	CLK3	 inhibitor.	Trophozoite	stage	of	wild	type	(Dd2)	or	mutant	(051C)	parasites	were	
purified	using	MACS	(magnetic	assisted	cell	sorting,	Milteny	Biotec)	purification	column	and	
treated	either	with	compound	TCMDC135051	(1µM)	or	solvent	DMSO	for	one	hour	at	37°C.	
Following	 inhibitor	 treatment	 the	parasites	were	 treated	with	0.1%	 saponin	 in	phosphate	
buffer	 saline	 (PBS)	 for	 one	 minute	 on	 ice	 to	 release	 parasites	 from	 host	 erythrocyte.	
Parasites	 were	 washed	 twice	 with	 PBS	 and	 the	 parasite	 pellets	 were	 used	 for	 total	 RNA	
isolation	using	RNeasy	Lipid	Tissue	Kit	(Qiagen).	Bioanalyzer	2100	instrument	(Agilent)	was	
used	to	assess	the	integrity	of	RNA	samples	and	samples	with	RNA	integrity	score	of	>8	were	
used	 for	 the	 array	 experiment.	 cDNA	 was	 prepared	 from	 the	 RNA	 samples	 using	 cDNA	
synthesis	kit	(Agilent)	and	equal	amounts	of	cDNAs	(amount	200ng)	were	labeled	with	Cy3	
label	 and	 the	 equal	 incorporation	 of	 label	 was	 confirmed	 by	 NanoDrop.	 	 Custom	 DNA	
microarray	 slides	 were	 prepared	 (Agilent)	 that	 contained	 14353	 unique	 probes	 covering	
5752	P.	falciparum	genes	as	described	before	by(31).	Microarray	slides	were	hybridized	with	
labeled	 cDNA	 samples	and	 intensity	of	 label	 in	each	probe	of	 the	array	were	acquired	by	
Agilent	 G2505C	 Microarray	 scanner.	 	 Normalized	 data	 from	 four	 independent	 biological	
replicates	 were	 used	 to	 identify	 probes	 showing	 at	 least	 two-fold	 change	 between	 the	
control	samples	and	inhibitor	treated	samples.	Statical	significance	(p-value	0.5<)	between	
the	control	and	treated	samples	were	calculated	using	moderate	T-test	analysis.	
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Liver	stage	development	assay	
Plasmodium	berghei	sporozoites	expressing	Luciferase	were	freshly	collected	from	salivary	
gland	 of	 Anopheles	 stephensi	 mosquitos	 to	 be	 used	 for	 measurement	 of	 inhibition	 of	
exoerythrocytic	 form	 (EEF)	 development	 by	 drug	 treatment.	 The	 freshly	 collected	
sporozoites	were	used	for	infection	of	human	hepatocarcinoma	HepG2	cells	expressing	the	
tetraspanin	CD81	 receptor	 (HepG2-A16-CD81EGFP	 cells).	HepG2	 cells	were	pretreated	 for	
18	hours	with	the	inhibitor	before	infection	with	P.	berghei	sporozoites.	After	infection,	the	
HepG2	cells	were	further	treated	with	the	drug	at	concentrations	shown	for	48	hours	and	
the	 inhibition	 of	 EEF	 development	 were	measured	 by	 bioluminescence.	 Atovaquone	 and	
DMSO	treatments	were	used	as	positive	and	negative	controls	in	the	microtitre	based	plate	
assay.	pEC50	value	of	the	inhibitor	for	inhibition	of	sporozoite	development	were	generated	
using	bioluminescence	values.	
	
P.	berghei	blood	stage	development	assay	
P.	berghei	ANKA	strain	of	parasite	was	used	for	infection	of	Balb/c	mice.	Blood	of	P.	beghei	
infected	mice	were	 collected	 at	 parasitaemia	 of	 1-3%	 and	 the	 parasites	were	 allowed	 to	
grow	 in	 in	 vitro	 for	 24	 hour,	 which	 allowed	 the	 parasites	 to	 synchronize	 at	 late	 schizont	
stage.	Mice	were	infected	with	late	schizont	P.	berghei	parasites	for	2-4	hours	that	allowed	
schizonts	 to	 rupture	 and	 form	 nascent	 ring	 stage	 of	 the	 parasite.	 Ring	 stage	 parasite	
infected	RBCs	were	collected	from	the	mice	and	treated	with	drug	at	eight-point	dilution	for	
22-24	 hours	 at	 370C	 in	 a	 microtitre	 plate.	 Following	 inhibitor	 treatment,	 parasites	 were	
stained	with	Hoechst	DNA	stain	and	acquired	by	flow	cytometry	to	measure	percentage	of	
schizont-infected	 cells.	 Artemisinin	 and	 DMSO	 treatments	 were	 used	 as	 positive	 and	
negative	control.	Growth	inhibitory	concentrations	were	calculated	using	Prism	7	software.	
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Stage	II	gametocyte	inhibition	assay	
P.	falciparum	Pf2004	strain	of	parasites	expressing	tdTom	as	marker	for	stage	II	gametocyte	
were	used	to	measure	inhibition	of	gametocyte	development	by	the	inhibitor,	as	previously	
described	(46).	At	28	hours	post	invasion	(28hpi)	the	regular	culture	medium	was	replaced	
with	 serum-free	 medium	 (-SerM)	 complemented	 with	 a	 minimal	 fatty	 acid	 mixture	 and	
bovine	serum	albumin	(0.39%	fatty	acid-free	BSA	and	oleic	and	palmitic	acid	[30	μM	each;	
added	from	30	mM	ethanol-solved	stocks])	to	induce	sexual	commitment.	After	20	hours	of	
incubation	 in	 -SerM	 the	 medium	 was	 replaced	 with	 complete	 medium	 containing	 10%	
serum	 for	 the	 remainder	 of	 the	 experiment.	 Inhibitor	 at	 eight-point	 dilutions	 starting	 at	
20µM	was	added	at	28hpi,	 and	 it	was	maintained	 for	42	hours	 to	 study	 the	effect	of	 the	
inhibitor	on	early	gametocyte	(stage	II)	development.	Following	treatment	gametocytaemia	
was	measured	by	 flow	cytometry	using	 tdTom	 reporter	 fluorescence	as	a	 viability	marker	
(details	 on	 cytometry	 are	 given	 in	 (46).	 The	 inhibitory	 effect	 of	 the	 compound	 on	
gametocyte	development	was	calculated	using	Graph	Prism	7	software.	
	
Gametocyte	culture	and	exposure	to	drug	
Gametocytes	 of	 P.	 falciparum	 clone	 3D7	 were	 generated	 in	 vitro	 using	 standard	
methodology	to	produce	infectious	gametocytes	(47),	using	human	blood	obtained	from	the	
Scottish	National	Blood	Transfusion	Service	and	medium	containing	heat-inactivated	human	
serum	at	10%	(v/v).	Gametocyte	flasks	were	prepared	to	enable	a	mixture	of	D14	and	D17	
cultures	 to	be	 fed	to	mosquitoes	on	the	day	of	 the	 infectious	 feed.	Medium	was	changed	
daily	for	all	cultures.	
	 50	
The	gametocytes	were	exposed	to	drug	in	two	ways.	For	longer	exposure	times,	the	cultures	
were	split	into	6	separate	flasks	once	they	had	reached	stage	II,	and	from	that	stage	on	the	
medium	used	was	supplemented	with	drug	at	concentrations	of	0.25,	0.5,	1,	2	and	4	µM,	
with	medium	 for	 the	 control	 flask	being	 supplemented	with	an	equivalent	amount	of	 the	
drug	solvent	DMSO.	For	shorter	exposure,	separate	stage	V	gametocyte	flasks	were	split	24	
hours	before	the	feed,	and	exposed	to	medium	containing	1	or	2	µM	of	drug.		
	
Infection	of	mosquitoes	
Anopheles	 coluzzii	 (Ngousso	 strain)	 mosquitoes	 were	 reared	 under	 standard	 insectary	
conditions	(26±1°C,	80%	humidity,	12	hr	light:12	hr	dark	cycle).	Adult	mosquitoes	were	fed	
ad	libitum	on	5%	glucose	solution	containing	0.05%	(w/v)	4-aminobenzoic	acid	(PABA).	Five	
to	 seven	day	old	 female	mosquitoes	were	 infected	by	membrane	 feeding	of	 gametocytes	
using	 standard	 procedures	 (47).	 Briefly,	 gametocytes	 were	 pelleted	 from	 the	 cultures	 by	
centrifugation,	resuspended	in	equal	volumes	of	serum,	containing	the	same	concentration	
of	drug	they	were	previously	exposed	to),	and	mixed	with	1-2	volumes	of	uninfected	fresh	
blood	 at	 40%	haematocrit	made	up	 in	 serum	 containing	 the	 same	 concentration	of	 drug.	
The	final	gametocytaemia	 in	the	 infectious	blood	meal	was	always	above	0.7%,	but	varied	
between	experiments.	
Mosquitoes	were	allowed	to	feed	for	10	minutes.	Exflagellation	was	monitored	during	this	
period	 by	 microscopical	 observation	 (400x	 magnification)	 of	 a	 drop	 of	 the	 feed	material	
under	a	coverslip.	Exflagellating	centres	were	counted	over	50-100	fields.	Unfed	mosquitoes	
were	removed	from	the	pots.	Mosquitoes	were	maintained	under	insectary	conditions	and	
fed	ad	libitum	on	5%	glucose	solution	containing	0.05%	(w/v)	4-aminobenzoic	acid	(PABA).		
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Mosquitoes	were	examined	 for	oocyst	 infections	10-11	days	after	 the	 feed	by	 removal	of	
the	midgut	and	examination	of	the	entire	gut	for	oocysts	at	400x	magnification.		
and	medium	containing	heat-inactivated	human	serum	at	10%	(v/v).	Prevalence	of	oocysts	
in	mosquitoes	was	calculated	as	the	number	of	mosquitoes	with	oocyst	infection	/	number	
of	mosquitoes	dissected.	
To	 test	 for	 the	 effect	 of	 TCMDC-135051	 on	 gametocyte	 development	 and	 mosquito	
infection,	data	were	analysed	with	a	generalized	 linear	mixed-effect	model	 (GLMM)	using	
the	 package	 lme4	 (version	 1.1-19)	 (48)	 in	 R	 (version	 3.4.2)	 (49).	 Count	 data,	 such	 as	
gametocyte	 numbers	 and	 exflagellation	 were	 analysed	 using	 GLMMs	 with	 poisson	 error,	
and	 prevalence	 of	 infection	was	 analysed	 using	GLMMs	with	 binomial	 errors.	 All	 GLMMs	
included	experiment	number	as	a	random	effect.	The	residuals	of	the	models	(diagnostics)	
were	assessed	using	visual	 inspection	of	residual	versus	predicted	values	 (Homogeneity	of	
variance),	 Shapiro-Wilk	 tests	 (normality),	 and	 the	R	package	 aods3	 (overdispersion).	 In	 all	
cases	 the	 optimal	 model	 was	 selected	 by	 backward	 elimination	 of	 the	 maximal	 model	
containing	all	 fixed	effects	and	 their	 interactions	of	 interest,	and	 the	 random	effects	 (50).	
The	 variance	 in	 the	 predictor	 variable	 explained	 by	 the	 GLMM	 (both	 marginal	 and	
conditional	 R	 squared	 values,	 delta	 method)	 were	 calculated	 using	 the	 package	 MuMIn	
(v1.42.5),	implementing	the	methodology	of	Nakagawa,	Johnson	and	Schielzeth	(51).			
	
In	vivo	P.	berghei	infection	and	drug	treatment	
Drug	efficacy	 in	P.	 berghei	was	 assessed	using	 standard	Peters	 four	day	 suppression	 test.	
Briefly,	P.	berghei	ANKA	strain	 line	820cl1m1	parasites	(1x105)	were	 intraperitoneally	 (i.p.)	
injected	into	mice	at	day	zero.	Drug	dosing	started	1.5	hours	after	injecting	parasites.	Stock	
TCMDC-135051	was	prepared	in	1:1	mixture	of	DMSO	and	Tween-80	and	diluted	10	fold	in	
	 52	
sterile	 distilled	 water	 for	 a	 final	 vehicle	 concentration	 of	 5%	 Tween-80	 and	 5%	 DMSO.	
Control	mice	were	dosed	with	vehicle	(5%	Tween-80	5%	DMSO)	twice	daily	or	chloroquine	
(20mg/kg	in	1XPBS).	All	drug	and	vehicle	injections	were	delivered	by	i.p.	Parasiteamia	was	
monitored	daily	from	day	4	by	taking	blood	smears	and	flow	cytometry.	Percentage	parasite	
suppression	 was	 calculated	 on	 Day	 4	 using	 the	 formula:	 100	 –	 (mean	 parasitaemia	 in	
treatment	group/mean	parasitaemia	in	vehicle	*	100).	
	
Expression	and	purification	of	human	PRPF4B		
The	kinase	domain	 (residues	669-1005)	of	human	PRPF4B	was	cloned	 into	vector	pFB-LIC-
Bse	(GenBank	ID	EF199842)	downstream	of	an	amino-terminal	tag	of	23	residues	consisting	
of	a	hexa-histidine	tag	(6xHis)	and	a	TEV-protease	site	for	tag	removal.	The	resulting	plasmid	
was	used	to	generate	bacmid	DNA	in	E.	coli	DH10Bac	cells,	followed	by	virus	assembly	in	Sf9	
cells	(Invitrogen	Bac-to-Bac	Expression	System).	For	the	expression	of	PRPF4B,	2	L	cultures	
of	suspended	Sf9	cells	were	grown	at	27°C	in	Insect-XPRESS	media	(Lonza)	to	a	density	of	2	x	
106	cells/mL,	before	being	infected	with	P2	baculovirus.	After	72	h,	cells	were	harvested	by	
centrifugation	 at	 900	 ×	 g	 for	 30	minutes	 at	 4oC.	 The	 cell	 pellet	was	 resuspended	 in	 Lysis	
Buffer	 (50	mM	HEPES	pH	7.5,	500	mM	KOAc,	50	mM	arginine,	50	mM	glutamate,	10	mM	
imidazole,	10%	glycerol,	2	mM	TCEP	and	protease	 inhibitor	cocktail	 (Millipore	Set	 III))	and	
stored	at	-85oC	until	use.	To	purify	PRPF4B	protein,	cells	were	disrupted	by	sonication	in	5	
cycles	of	5	second	pulses	(35%	max	amplitude,	Sonics	VCX750)	with	10	second	intervals,	on	
ice.	 To	 clear	 up	 debris,	 polyethyleneimine	 pH	 7.5	 was	 added	 to	 the	 lysate	 to	 a	 final	
concentration	of	0.15%	(w/v)	and	the	sample	was	centrifuged	at	20,000	×	g	 for	45	min	at	
4°C.	 The	 supernatant	 was	 loaded	 onto	 a	 5	mL	 HisTrap	 FF	 Crude	 column	 (GE	 Healthcare)	
which	 was	 washed	 in	 Lysis	 Buffer	 containing	 30	 mM	 imidazole	 until	 the	 UV	 absorbance	
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reached	baseline,	 before	 PRPF4B	 elution	 by	 isocratic	wash	 in	 10	 column-volumes	 of	 Lysis	
Buffer	 containing	300	mM	 imidazole.	 In	order	 to	 cleave	 the	N-terminal	6xHis-tag,	PRPF4B	
was	mixed	with	N-terminal	 His-tagged	 TEV	 protease	 (about	 15:1	molar	 ratio	 of	 kinase	 to	
protease)	 and	dialyzed	overnight	 at	 4oC	 against	 20	mM	HEPES	pH	7.5,	 500	mM	KOAc,	 50	
mM	arginine,	50	mM	glutamate,	5%	(v/v)	glycerol,	2	mM	TCEP.	PRPF4B	was	then	re-purified	
by	 affinity	 chromatography	 on	Ni-sepharose	 followed	 by	 gel	 filtration	 on	 a	 Superdex	 200	
16/60	column	(GE	Healthcare)	pre-equilibrated	in	20	mM	Tris·HCl	pH	8.0,	200	mM	NaCl,	5	
mM	 TCEP.	 The	 elution	 peak	 was	 analyzed	 by	 SDS-PAGE,	 pooled	 and	 concentrated	 to	 16	
mg/mL	 by	 ultrafiltration	 (Centriprep	 devices	 with	 10	 kDa	 MW	 cut-off).	 The	 final	 sample	
concentration	 was	 determined	 by	 UV	 absorbance	 using	 a	 NanoDrop	 spectrophotometer	
(Thermo	 Scientific)	 with	 the	 calculated	 molecular	 weight	 of	 39.54	 kDa	 and	 estimated	
extinction	coefficient	of	27,850	M-1.cm-1	at	280	nm.	
	
Differential	scanning	fluorimetry	(DSF)	analysis.	
PRPF4B	protein	was	thawed	from	storage,	diluted	to	2	µM	in	ice-cold	buffer	containing	50	
mM	HEPES	 pH	 7.5,	 150	mM	NaCl,	 10	mM	MgCl2,	 1	mM	EGTA	 and	 5X	 SYPRO	orange	 dye	
(Invitrogen,	S-6650).	Protein/dye	solution	was	transferred	to	a	384-well	PCR	plate	with	25	
µL/well	 plus	 0.5	 uL	 of	 1	 mM	 test	 compounds	 in	 DMSO	 (2%	 final	 DMSO	 concentration).	
Thermal	shift	data	was	acquired	in	a	qPCR	instrument	(Applied	Biosystems	QuantStudio	6)	
programmed	 to	 equilibrate	 the	 plate	 at	 25oC	 for	 5	 min	 followed	 by	 ramping	 the	
temperature	from	20	to	95oC	at	a	constant	rate	of	0.05oC	per	sec.	Data	was	processed	using	
Protein	 Thermal	 shift	 software	 (Applied	 Biosystems)	 fitting	 experimental	 curves	 to	 a	
Boltzmann	function	to	calculate	differential	thermal	shifts	(dTm)	referenced	to	protein/dye	
in	2%	DMSO.	
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PRPF4B	enzymatic	assay.	
Enzyme	activity	was	measured	using	100	nM	human	PRPF4B	in	an	assay	buffer	consisting	of	
20	mM	HEPES	pH	7.5,	250	mM	NaCl,	10	mM	MgCl2,	2.5%	glycerol	and	1	mM	DTT	plus	10	µM	
of	a	modified	PAK4	peptide	([biotin]-GGGRDSPPPPAR-[OH])	and	2	mM	ATP	in	a	total	volume	
of	100	µL,	incubated	at	30oC	for	4	h.	The	final	assay	pH	was	measured	as	pH	7.5.	To	stop	the	
reactions	 and	 prepare	 samples	 for	mass	 spectrometry	 analysis,	 40	 µL	 of	 reaction	 volume	
was	 taken	 and	 20	 µL	 of	 3%	 formic	 acid	was	 added.	 For	measuring	 the	 effect	 of	 TCMDC-
135051	on	the	activity	of	PRPF4B,	we	preincubated	TCMDC-135051	or	Compound-A	(1)	or	
trifluoroacetic	 acid	 (TFA)	 in	 the	 range	 of	 0.005	 to	 100	 µM	 (2x	 final	 concentration)	 with	
PRPF4B	 in	 assay	 buffer	 (also	 at	 2x	 final	 concentration)	 for	 30	 min	 at	 room	 temperature	
before	 initiating	 the	reaction	by	mixing	with	a	2x	solution	of	peptide	and	ATP.	Compound	
serial	 dilutions	 (3-fold)	were	made	 in	 100%	DMSO	 at	 50x	 assay	 concentration	 before	 the	
dilution	 to	2x	 final	concentration	 in	2x	PRPF4B	plus	assay	buffer	 (4%	DMSO)	and	the	 final	
dilution	to	1x	concentration	(2%	DMSO).	Compound-A,	with	a	reported	IC50	of	16	nM	against	
PRPF4B,	was	 used	 as	 a	 control	while	 trifluoroacetic	 acid,	 present	 as	 a	 counter	 ion	 in	 the	
TCMDC-135051	sample,	was	tested	to	rule	out	any	inhibition	of	PRPF4B.	
	
Mass	spectrometry	(MS)	analysis	of	PRPF4B	enzymatic	assay.	
The	ratio	between	non-phosphorylated	and	phosphorylated	PAK4	peptide	was	analysed	by	
intact	peptide	mass	analysis	using	1	µL	of	the	reaction	medium	by	reverse	phase	HPLC-ESI-
MS	in	an	Acquity	H-Class	HPLC	system	(Waters	Corp.	Milford,	MA,	USA)	directly	connected	
to	a	XEVO	G2-Xs	QToF	(Waters).	The	HPLC	was	equipped	with	a	C18	column	(ACQUITY	UPLC	
Protein	BEH	C18	Column,	1.7	µm,	2.1	mm	X	50	mm,	Waters)	for	small	molecule	separation	
kept	at	45°C.	The	mobile	phase	solvent	A	was	0.1%	formic	acid	(FA)	in	water,	and	solvent	B	
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was	 0.1%	 FA	 in	 100%	 Acetonitrile	 (ACN).	 The	 samples	 were	 loaded	 at	 a	 flow	 rate	 of	 0.5	
uL/min,	and	eluted	from	the	C18	column	at	a	flow	rate	of	400	uL/min	with	a	linear	gradient	
step	of	3%	to	90%	solvent	B	over	2.5	min.	The	column	was	regenerated	by	washing	at	100%	
solvent	B	for	1.5	min	and	re-equilibrated	at	1%	solvent	B	for	3	min.	Exact	mass	analysis	was	
performed	 in	 positive	 ion	 electrospray	 mode.	 For	 internal	 calibration,	 the	 LockSpray	 ion	
source	properties	were	the	following:	Scan	time	was	fixed	at	0.5	sec,	with	a	mass	window	of	
0.5	Da	around	Leu-enkephalin	(556.2771	Da).	The	ToF-MS	acquisition	ranged	from	50	Da	to	
2000	Da	with	a	scan	time	fixed	at	0.5	sec.	The	cone	voltage	on	the	ESI	source	was	fixed	at	40	
V.	 The	 system	was	 controlled	with	MassLynx	 software	 (ver.	 4.1)	 and	 data	was	 processed	
using	TargetLynx	tool.	
TargetLynx	 software	was	 used	 to	 integrate	 the	 peak	 area	 of	 the	 eluted	 peptide	 from	 the	
total	 ion	chromatogram	(TIC).	We	focused	on	the	following	mass	over	charge	ratios	(m/z):	
1389.66	 (+1	charge),	695.33	 (+2	charges)	and	463.89	 (+3	charges)	 for	non-phosphorylated	
PAK4	 peptide	 and,	 1469.66	 (+1	 charge),	 735.32	 (+2	 charges)	 and	 490.55	 (+3	 charges)	 for	
phosphorylated	PAK4	peptide.	The	predicted	retention	times	were	2.7	and	2.8	min	for	the	
non-phosphorylated	 and	 phosphorylated	 peptide	 respectively.	 The	 retention	 times	 were	
3.03	and	3.05	min	for	non-phosphorylated	and	phosphorylated	peptides,	respectively.	
	
Gene	ontology	(GO)	enrichment	analysis	
Gene	 ontology	 (GO)	 enrichment	 analysis	 was	 carried	 out	 using	 the	 Fisher's	 Exact	 test	 to	
compare	the	proportion	of	genes	in	a	set	annotated	with	each	GO	term	with	the	proportion	
of	 genes	 in	 the	 background	 annotated	with	 the	 same	 term	 as	 implemented	 in	 PlasmoDB	
(cite	 this	 paper:	https://www.ncbi.nlm.nih.gov/pubmed/27903906).		 Multiple	 test	
correction	was	carried	out	using	the	Benjamini	Hochberg	method.	
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DNA	primers	used	
CLK1-FamB1	
AGGAGATATACATATGGATGATGAAATTGTCCATTTTAGTTGG	
CLK1-FamB2	
GAAGTACAGGTTCTCTTCAAGGAACTTGTGCTTTAATAATTCG	
CLK3-HR1	
ATGCGTTAACGAAATACCATCTAATCCATCATATATCGACC	
CLK3-HR2	
ATGCAGATCTATATTTTATACTACTTAATAAACGAATGATGTGCCT	
CLK3_BglII-KN1	
Cattcgaacactaagcataaatgatttttatattttatactacttaataaacgaatgatgtgccttttattgtcc	
CLK3_BglII-KN2	
Ggacaataaaaggcacatcattcgtttattaagtagtataaaatataaaaatcatttatgcttagtgttcgaatg	
CLK3-G449P1	
Gggcaatacgcagattgggccacatccattcgaaca	
CLK3-G449P2	
Tgttcgaatggatgtggcccaatctgcgtattgccc	
P1		
GTATTTTCAGGGCGCCCagaatgatcagataaataaagattataacaatga	
P2		
GTGCTATTCTTAAGTTACCCCACATCCA	
P3	
CGAACACAAGAAAATGAGGATAAACTTCTAG	
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P4	
CGCATGTGACGCAGGGCA	
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Fig.	S2	
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Fig.	S3	
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Fig.	S4	
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Fig.	S5	
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Fig.	S6	
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Fig.	S7	
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Fig.	S8	
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Fig.	S9	
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Fig.	S10	
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Fig.	S11	
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Fig.	S12	
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Fig.	S13	
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Fig.	S1.	Sequence	alignment	of	PfCLK1,		PfCLK3	and	mammalian	PKA		
Shown	in	red	is	the	glycine	rich	loop,	purple	the	kinase	region	V	in	PfCLK1	and	PfCLK3,	the	
glycine	 in	 position	 449	 in	 PfCLK3	 (which	 is	 mutated	 to	 proline	 in	 the	 G449P	 mutant	
described	here)	and	corresponding	amino	acids	in	PfCLK1	and	PKA	(highlighted	in	red).	Also	
shown	are	the	“DFG	and	“APE”	motifs	that	represent	the	start	and	finish	of	the	activation	
loop,	respectively.	
.
	=	similar	residue,		:	=	conserved	residues	and	the	*	=	identical	residues.	
	
Fig.	S2.	Generation	of	a	HTS	screen	for	PfCLK1	and	PfCLK3	
(A)	 Gel	 based	 assay	 of	 the	 phosphorylation	 of	 myelin	 basic	 protein	 (MBP)	a-casein	 and	
histone	 by	 recombinant	 PfCLK1	 and	 PfCLK3.	 The	 top	 gel	 is	 an	 autoradiograph	 and	 the	
bottom	a	Commassie	 stain	of	 the	 same	gel	 as	 a	 loading	 control.	 The	position	of	MBP,	a-
casein	and	histone	are	shown.	(B)	Measure	of	Vmax	and	Km	for	ATP	of	recombinant	PfCLK3	
(C)	 Linear	 relationship	between	 the	activity	 read	out	of	 the	TR-FRET	kinase	assay	and	 the	
concentration	of	PfCLK3	using	in	the	kinase	reaction.	(D)	Time	course	of	the	TR-FRET	kinase	
reaction	for	PfCLK1	when	used	at	an	enzyme	concentration	of	40nM.	(E)	Measure	of	Vmax	
and	Km	for	ATP	of	recombinant	PfCLK1	(F)	Linear	relationship	between	the	activity	read	out	
of	 the	TR-FRET	kinase	assay	and	 the	concentration	of	PfCLK1	using	 in	 the	kinase	 reaction.	
(G)	 Time	 course	 of	 the	 TR-FRET	 kinase	 reaction	 for	 PfCLK1	 when	 used	 at	 an	 enzyme	
concentration	 of	 40nM.	 (h)	 Scheme	 of	 the	 assay	 protocol	 for	 PfCLK1	 and	 PfCLK3	 high-
throughput	 screens.	 The	data	 shown	 in	 the	graphs	are	 the	mean	±S.E.M	of	 at	 least	 three	
independent	experiments.		
	
	
	 72	
	
	Fig.	S3.	Structures	of	hits	from	the	HTS	screen	against	PfCLK1	and	PfCLK3.		
Concentration-response	curves	of	compounds	that	inhibited	PfCLK1	or	PfCLK3	were	obtain	
and		those	compounds	that	had	pIC50	values	that	were	>1.5	fold	different	between	PfCLK1	
and	PfCLK3	were	considered	specific	whilst	those	that	showed	<1.5	fold	difference	in	pIC	
values	were	considered	as	pan-active.	Shown	are	exemplar	molecules	from	each	
classification.	
	
Fig.	S4.	TCMDC-135051	does	not	inhibit	the	human	orthologue	of	PfCLK3,	PRPF4B.	
(A)	Measurement	 of	 melting	 temperature	 of	 PRPF4B	 in	 the	 presence	 of	 a	 10-fold	 molar	
excess	 of	 TCMDC-135051	 (20µM).	 	 Staurosporine	 was	 used	 as	 a	 positive	 control	 or	 2%	
DMSO	 as	 a	 vehicle	 control.	 Data	 was	 measured	 in	 triplicate	 with	 repeats	 indicated	 in	
parenthesis.	 	 (B)	 Concentration-response	 curve	 of	 inhibition	 of	 PRPF4B	 activity	 in	 the	
presence	 of	 TCMDC-135051	 (co-purified	 with	 trifluoroacetic	 acid),	 Compound-A	 or	
trifluoroacetic	 acid	 (TFA).	 Data	 was	 measured	 in	 duplicate.	 Compound	 A	 curve	 was	
calculated	using	the	logistic	non-linear	regression	analysis	implemented	in	GraphPad	Prism,	
while	 fitting	 for	 TFA	 and	 TCMDC-135051	 was	 generated	 as	 a	 linear	 regression	 using	 the	
same	software.	Data	shown	is	the	mean	±	SEM	of	three	independent	experiments.	
	
Fig.	S5.	TCMDC-135051	activity	against	PfCDPK1	and	PfPKG	
Gel	based	assay	of	the	phosphorylation	of	myelin	basic	protein	(MBP)	by	(A)	PfCDPK1,	 (B)	
PfPKG	and	(C)	PfCLK3.	The	top	gel	is	an	autoradiograph	and	the	bottom	a	Commassie	stain	
of	 the	same	gel	as	a	 loading	control.	The	position	of	MBP	and	auto-phosphoryated	kinase	
and	the	recombinant	kinase	is	shown.	
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Fig.	S6.	Series	of	related	molecules	identified	from	HTS	as	PfCLK3	inhibitors	
TR-FRET	 assay	 of	PfCLK3	 activity	was	 used	 to	 generate	 concentration	 inhibition	 curves	 of	
TCMDC-135049,	 TCMDC-135050	 and	 TCMDC-135051.	 Shown	 is	 the	 mean	 of	 three	
experiments	±	S.E.M).	
	
Fig.	S7.	Enzymatic	kinetics	of	PfCLK3	and	the	G449P	variant	and	growth	rates	of	mutant	
parasites	expressing	G449P.	
(A)	Measure	of	recombinant	PfCLK3	and	G449P	at	various	concentrations	of	ATP.	The	data	
shown	is	the	mean	±S.E.M	of	at	least	three	independent	experiments.	(B)	The	multiplication	
rate	of	the	A3	strain	of	G449P	mutant	parasites	was	tested	together	with	that	parent	3D7	
strain.	The	starting	parasitaemia	was	0.3%	and	the	increase	in	parasitaemia	measured	after	
52	 hours	 (one	 cycle).	 Multiplication	 rate=parasitaemia	 at	 52	 hours(%)/initial	
parasitaemia(%).		The	data	presented	is	the	mean	±S.E.M	of	three	determinations.		
	
Fig.	S8.	Biological	function	of	genes	that	are	down	regulated	by	PfCLK3	inhibition.	
Gene	ontology	enrichment	analysis	showing	biological	function	of	genes	significantly	down	
regulated	 by	 TCMDC-135051	 treatment	 in	 Dd2	 parasites.	 Biological	 functions	 with	 FDR	
<0.05	 ((calculated	using	 the	Benjamini	Hochberg	method)	are	 shown	 (see;	Supplementary	
Table	S5	full	data	set).		
	
Fig.	S9.	Comparison	of	the	enzyme	kinetics	of	PvCLK3	and	PbCLK3.	
Measure	 of	 recombinant	 PfCLK3	 and	 PbCLK3	 at	 various	 concentrations	 of	 ATP.	 The	 data	
shown	is	the	mean	±S.E.M	of	at	least	three	independent	experiments.	
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Fig.	S10.	Inhibition	of	PvCLK3	and	PbCLK3	by	TCMDC-135051.	
TR-FRET	in	vitro	kinase	assays	were	conducted	on	full	length	recombine	(a)	PvCLK3	and	(b)	
PbCLK3	in	the	presence	of	various	concentrations	of	TCDMC-135051.	Shown	at	the	mean	±	
SEM	of	three	independent	experiments.	
	
Fig.	S11.	Activity	of	TCMDC-135051	at	liver	invasion	and	sporozoite	development.	
Concentration	 effect	 curve	 of	 TCMDC-135051	on	P.	 berghei	 sporozoite	 development.	 The	
data	shown	are	the	mean	±S.E.M	of	at	least	three	independent	experiments.	
	
Fig.	 S12.	 Death	 curves	 of	 Pf2004	 blood	 stage	 and	 stage	 II	 gametocytes	 in	 response	 to	
TCDMC-135051.	
Parasite	viability	assays	were	conducted	on	(A)	Pf2004	parasite	strain	at	the	asexual	blood	
stage	and	(B)	Pf2004	stage	II	gametocytes.	Shown	at	the	mean	±	SEM	of	three	independent	
experiments.	
	
Fig.	 S13.	 Inhibition	 of	 PfCLK3	 at	 stage	 V	 gametocytes	 reduces	 transmission	 to	 the	
mosquito	vector.	
Concentration	 effect	 of	 exposure	 of	 P.	 falciparum	 (clone	 3D7)	 stage	 V	 gametocytes	 to	
TCMDC-135051	on	(A,B)	gametocyte	(GC)	numbers	in	culture,	(C,D)	exflagellation,	and	(E,F)	
prevalence	of	infection	of	An.	coluzzii	mosquitoes.	The	top	row	of	graphs	(A,C,E)	show	the	
mean	±SEM	of	4	independent	experiments.	The	lower	panels	show	the	predicted	effects	of	
drug	concentrations	according	to	the	maximal	GLMM	with	the	shaded	area	indicating	95%	
confidence	intervals.	From	the	GLMM	analysis	the	approximate	EC50	values	were	calculated.	
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Supplementary	Tables	
Supplementary	Table	S1.	Compound	Screen.	
Hits	 from	 the	 primary	 single	 dose	 HTS	 (2838)	 and	 compounds	 contained	 in	 the	 MMV-
malaria	box	 (259)	were	used	to	generate	concentration	 inhibitor	curves.	Shown	are	pIC50	
values	against	PfCLK3,	PfCLK1,	PvCLK3	and	hCLK2	(sheet	1).	These	data	are	divided	into	data	
associated	 with	 TCAMs/GSK	 compounds	 (sheet	 2),	 PKIS	 compounds	 (sheet	 3),	 MRCT	
compounds	(sheet	4)	and	MMV	compounds	(sheet	5).					
	
Supplementary	 Table	 S2.	 Transcription	 changes	 in	 parent	 P.	 falciparum	 strain	 Dd2	
following	treatment	with	TCMDC-135051.	
Sheet	1	–	Statistically	significant	changes	(t-test	n=4)	in	transcript	levels	following	treatment	
of	Dd2	parasites	at	trophozoite	stage	with	TCMDC-135051	(1µM	for	60	mins).	Shown	are	
the	probes	used	and	changes	associated	with	each	of	the	probes.	Sheet	2	–	Summary	of	the	
probes	that	reveal	significantly	down-regulated	genes	following	TCMDC-135051	treatment.	
Sheet	3	-	Summary	of	the	genes	that	are	significantly		down-regulated	following	TCMDC-
135051	treatment.	Sheet	4	-	Summary	of	the	probes	that	reveal	significantly	up-regulated	
genes	following	TCMDC-135051	treatment.	Sheet	5-	Summary	of	the	genes	that	are	
significantly	up-regulated	following	TCMDC-135051	treatment. 
		
Supplementary	 Table	 S3.	 Transcription	 changes	 in	 the	 resistant	 parasite	 strain	 TM051C	
following	treatment	with	TCMDC-135051.	
Sheet	1	–	Statistically	significant	changes	(t-test	n=4)	in	transcript	levels	following	treatment	
of	TM051C	parasites	at	trophozoite	stage	with	TCMDC-135051	(1µM	for	60	mins).	Shown	
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are	the	probes	used	and	changes	associated	with	each	of	the	probes.	Sheet	2	–	Summary	of	
the	probes	that	reveal	significantly	down-regulated	genes	following	TCMDC-135051	
treatment.	Sheet	3	-	Summary	of	the	genes	that	are	significantly	down-regulated	following	
TCMDC-135051	treatment.	Sheet	4	-	Summary	of	the	probes	that	reveal	significantly	up-
regulated	genes	following	TCMDC-135051	treatment.	Sheet	5-	Summary	of	the	genes	that	
are	significantly	up-regulated	following	TCMDC-135051	treatment. 
	
Supplementary	 Table	 S4.	 Transcription	 changes	 designated	 as	 a	 result	 of	 on-target	
inhibition	of	PfCLK3	and	a	comparison	with	essential	Plasmodium	falciparum	genes.	
Subtracting	 the	 genes	 where	 transcription	 was	 significantly	 changed	 following	 treatment	
with	 TCMDC-135051	 (1µM	 for	 60	mins)	 in	 TM051C	 parasites	 with	 those	 changed	 in	 Dd2	
parasites	 revealed	 the	 “on	 target”	 transcriptional	 changes	 associated	 with	 inhibition	 of	
PfCLK3.	Sheet	1	–	On	target	up-regulated	genes.	Sheet–2	 Identification	(highlighted)	of	the	
on	target	up	regulated	genes	that	are	essential	for	parasite	blood	stage	survival.	Sheet	3-	On	
target	 down-regulated	 genes.	 Sheet	 4-	 Identification	 (high-lighted)	 of	 the	 on	 target	 down	
regulated	genes	that	are	essential	for	parasite	blood	stage	survival.	
	
Supplementary	 Table	 S5.	 Gene	 ontology	 analysis	 of	 on-target	 down	 regulated	 genes	
following	inhibition	of	PfCLK3	in	Dd2	parasites.	
Gene	ontology	enrichment	analysis	was	carried	out	on	genes	that	were	significantly	down-
regulated	by	PfCLK3	inhibition.		GO	terms	with	P	<	0.05	(derived	from	the	Fisher's	Exact	test)	
and	with	FDR	values		<0.05		 (calculated	using	the	Benjamini	Hochberg	method)	are	shown	
on	 sheet	 1,	 whilst	 all	 Go	 terms	 with	 a	 P<0.05	 are	 shown	 on	 sheet	 2.	 From	 left	 to	 right,	
columns	show:	the	GO	term	id,	the	GO	term	name,	the	number	of	genes	in	the	background	
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annotated	with	 this	GO	 term,	 the	number	of	genes	 significantly	downregulated	by	PfCLK3	
inhibition	annotated	with	 this	GO	term,	a	 list	of	 the	downregulated	genes	annotated	with	
this	GO	term,	the	percentage	of	genes	in	the	background	annotated	with	this	GO	term	that	
also	appear	in	the	list	of	downregulated	genes,	the	fold	enrichment	of	the	GO	term	in	the	
downregulated	gene	list,	an	odds	ratio,	a	p-value	and	the	FDR.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
